Clinical Science (2016) 130, 57–77 doi: 10.1042/CS20150469

The natriuretic peptides system in the pathophysiology of heart failure: from molecular basis to treatment

Massimo Volpe*†, Marino Carnovali‡ and Vittoria Mastromarino*

*Cardiology Department, Clinical and Molecular Medicine Department, Sapienza University of Rome, 00189 Rome, Italy
†IRCCS Neuromed, 86077 Pozzilli, IS, Italy
‡Rehabilitation Department, A.O. “G. Salvini” 20024 Garbagnate Milanese, Milan, Italy

Abstract

After its discovery in the early 1980s, the natriuretic peptide (NP) system has been extensively characterized and its potential influence in the development and progression of heart failure (HF) has been investigated. HF is a syndrome characterized by the activation of different neurohormonal systems, predominantly the renin–angiotensin (Ang)–aldosterone system (RAAS) and the sympathetic nervous system (SNS), but also the NP system. Pharmacological interventions have been developed to counteract the neuroendocrine dysregulation, through the down modulation of RAAS with ACE (Ang-converting enzyme) inhibitors, ARBs (Ang receptor blockers) and mineralocorticoid antagonists and of SNS with β-blockers. In the last years, growing attention has been paid to the NP system. In the present review, we have summarized the current knowledge on the NP system, focusing on its role in HF and we provide an overview of the pharmacological attempts to modulate NP in HF: from the negative results of the study with neprilysin (NEP) inhibitors, alone or associated with an ACE inhibitor and vasopeptidase inhibitors, to the most recently and extremely encouraging results obtained with the new pharmacological class of Ang receptor and NEP inhibitor, currently defined ARNI (Ang receptor NEP inhibitor). Indeed, this new class of drugs to manage HF, supported by the recent results and a vast clinical development programme, may prompt a conceptual shift in the treatment of HF, moving from the inhibition of RAAS and SNS to a more integrated target to rebalance neurohormonal dysregulation in HF.

Key words: bradykinin, heart failure, LCZ696 (sacubitril/valsartan), natriuretic peptides, neprilysin, neuroendocrine syndrome.

NEUROHORMONAL ACTIVATION IN CHRONIC HEART FAILURE

Chronic heart failure (HF) is a syndrome with a complex pathophysiology in which the neuroendocrine activation plays a significant role. The pathophysiology of HF is indeed characterized by an early activation of different neurohormonal systems [i.e., sympathetic nervous system (SNS) and natriuretic peptides (NPs)] in the presence of asymptomatic left ventricular (LV) systolic dysfunction [1–4]. In the early stages of HF, the SNS and renin–angiotensin (Ang)–aldosterone system (RAAS) response play a compensatory role, aimed at supporting cardiac output and increasing peripheral vasoconstriction in an effort to maintain circulatory homeostasis. However, the prolonged activation of the two systems becomes detrimental and contributes to progression and worsening of HF, eventually leading to congestion. In addition to the classical components of neuroendocrine activation other regulatory systems are involved, i.e. kinins, NPs, endothelin, erythropoietin, prostaglandins and adrenomedullin [5,6]. If the activation of SNS and RAAS results in unfavourable consequences and a negative prognostic affect, the activation of kinins and NP systems might play a favourable role.
Therefore, pharmacological interventions aimed at re-balancing the neuroendocrine dysregulation in HF are effective and beneficial. So far, the therapeutic approach has been based on pharmacological interventions to down-modulate RAAS, through Ang-converting enzyme (ACE) inhibitors [7–12] or Ang receptor blockers (ARBs) [13–16], aldosterone [17–20] and also through mineralocorticoid receptor antagonists (MRA) and SNS by β-blockers [21–26]. Hence, triple-therapy with ACE inhibitors (or, if not tolerated, an ARB), β-blockers and MRA, currently represents the standard, optimal therapeutic approach (Figure 1). Triple-therapy improves symptoms and quality of life and provides protection against major fatal and non-fatal events, thus reducing hospitalization and mortality. If, for some reason, a patient cannot tolerate an MRA in addition to an ACE inhibitor and a β-blocker, an ARB can be tried as an alternative [15]. In addition to the triple-therapy, the treatment of HF include also vasodilators, as nitrates, and diuretics that are important to relieve signs and symptoms of congestion, inotropes and non-pharmacological tools such as implantable cardioverter-defibrillator, cardiac resynchronization therapy, mechanical ventricular assistance and heart transplantation [26].

**UNMET THERAPEUTIC NEEDS IN HEART FAILURE**

In spite of an optimized therapy for the control of neuroendocrine activation and a consequent decline of hospital mortality
[27], the quality of life and prognostic outlook for those HF patients who survive after an acute hospitalization remain poor [28]. Data suggest that HF-related survival rates are as poor as those associated with cancer. For example, in the original and subsequent Framingham cohort, 62% and 75% of men and 38% and 42% of women respectively, died within 5 years of being diagnosed with HF [29,30]. In comparison, 5-year survival for all cancers among men and women in the US during the same period was approximately 50%.

Therefore, in spite of the current approach to neuroendocrine modulation in HF, clinical goals remain largely unaccomplished and more thorough approaches to address neurohormonal dysregulation may be needed. From this point of view, the modulation of systems that promote favourable effects in HF, such as kinins and NP systems, has long been viewed as attractive and rational to implement benefits of RAAS and SNS blockade [31].

The block of bradykinin breakdown is potentially beneficial, because bradykinin has useful actions in HF [32]. Augmentation of bradykinin may promote vasodilation, fibrinolytic effects and inhibition of cellular growth and division, which may contribute to the benefits of ACE inhibitors [33–35]. An excess of bradykinin accumulation however may cause adverse effects, such as cough, rash, hypotension and angioedema [35]. A more promising strategy is represented by an empowerment of the NP system, which so far has not been effectively and safely attained in clinical practice.

**NATRIURETIC PEPTIDES SYSTEM**

The cardiac endocrine function was first identified more than 30 years ago [36]. Since then, a growing number of experimental and clinical studies have been performed to investigate its components, regulation and function. Overall, many advances have been made in the field, consolidating the concept that the endocrine function of human heart is a relevant component of a complex network including endocrine, nervous and immune systems. In 1981, de Bold et al. [36] found that the intravenous injection of atrial, but not ventricular, homogenates into rats elicited a rapid decrease in blood pressure that was accompanied by increased renal sodium and water excretion. After this fundamental observation, several groups purified peptides of variable size from atrial tissue provided with both natriuretic and vascular smooth muscle-relaxing activity [37–40]. These peptides were collectively named atrial NP (ANP) or factor. B-type NP (BNP), which was originally called brain NP [41] and C-type NP (CNP) were subsequently purified from porcine brain extracts based on their ability to relax smooth muscle [42].

**Atrial natriuretic peptide**

All NPs are synthesized as preprohormones (Figure 1). Human pre-proANP is 151-amino acids in length. Cleavage of the N-terminal signal sequence results in the 126-amino acid proANP, which is the predominant form stored in atrial granules. ProANP is rapidly cleaved upon secretion by the transmembrane cardiac serine protease to form the biologically-active C-terminal 28-amino acid peptide and the biologically inactive fragment (98 amino acid) of the ANP prohormone [N-terminal proANP (NT-proANP); 43]. Alternative processing of proANP by an unknown protease in the kidney generates a 32-residue peptide called urodilatin, which may be important in regulating renal sodium and water excretion [44].

ANP is primarily expressed and stored in granules in the atria, although it is present at lower concentrations in other tissues, such as the ventricles and kidney. The primary stimulus for ANP release is atrial wall stretch resulting from increased intravascular volume [45,46] or cardiac transmural pressure which may promote ANP expression and biosynthesis in the ventricles in conditions such as HF. Once secreted, ANP perfuses into the coronary sinus, which facilitates distribution to its various target organs in a true endocrine manner. Hormones such as endothelin [47], Ang [48] and arginine–vasopressin [49] stimulate ANP release [50].

Plasma levels of ANP in normal patients are approximately 10 fmol/ml (20 pg/ml) and are elevated 10–100-fold in patients with congestive HF [51,52]. Both ANP and NT-proANP have been used as markers for the diagnosis of asymptomatic LV dysfunction [53] and plasma ANP levels have been shown to correlate with the severity of symptomatic HF. However, in the last few years, due to higher stability, BNP measures were preferred to ANP for diagnostic and prognostic use in HF [54].

**B-type natriuretic peptide**

BNP was initially purified from porcine brain extracts and hence defined brain NP [41]. However, it was subsequently found in much higher concentrations in cardiac ventricles from patients or animals undergoing cardiac stress such as congestive HF or myocardial infarction [52]. Therefore, it is currently referred to as BNP or B-type NP. Human BNP is synthesized as a preprohormone of 134 residues, containing a signal sequence that is cleaved to yield a 108-amino acid prohormone (Figure 1). The 108 amino acid precursor, proBNP, produced in cardiomyocytes, is cleaved between residues 76 and 77 by the processing enzymes corin or furin to produce the biologically-active 32-amino acid BNP plus the 76-amino acid N-terminal peptide [N-terminal proBNP (NT-proBNP)]. All three peptides proBNP, BNP and NT-proBNP are secreted by the heart and circulate in humans. Fully processed BNP length varies among species; human BNP is 32 amino acids [55].

Actually, the introduction of sensitive MS methods have led to the identification of many new low molecular mass circulating forms of BNP and the absence or near-absence of the 32-amino acid form in some subjects. In patients with HF, BNP(1–32) form is a minor constituent in peripheral plasma being rapidly truncated to BNP(3–32) upon incubation in plasma. This process is catalysed by the enzyme dipeptidyl peptidase IV (DPP IV), which rapidly removes the N-terminal serine-proline dipeptide from BNP. These truncated forms [BNP(3–32) or BNP(8–32)] elicit reduced natriuretic, diuretic and vasodilatory responses and increase urinary cGMP to a lesser extent than BNP(1–32), probably because of a more rapid degradation compared with BNP(1–32). DPP IV also cleaves a similar histidine-proline dipeptide off the N-terminal end...
of proBNP, although at a 4-fold slower rate, to produce the truncated proBNP(3–108) form. This peptide circulates at relatively low concentrations in normal subjects, but proBNP(3–108) concentrations are raised in patients with asymptomatic LV dysfunction or HF (fiftieth percentiles 8, 18 and 43 pmol/l respectively) [56].

Although BNP is stored with ANP in atrial granules, BNP is not stored in granules in the ventricles. Instead, ventricular BNP production is transcriptionally regulated by cardiac wall stretch resulting from volume overload or increased transmural gradient [57]. Healthy individuals have plasma BNP concentrations of approximately 1 fmol/ml (3.5 pg/ml). In patients with congestive HF plasma BNP concentration, as well as those of the inactive precursor NT-proBNP, increase up to 100-fold [53]. Both these peptides are commonly used as ‘rule-out’ test in the diagnosis of HF and as markers of prognosis in chronic HF. NT-proBNP concentrations in healthy individuals are approximately of 51 pg/ml, cut-off levels are 300 pg/ml for the diagnosis of acute HF and 125 pg/ml for chronic HF. For BNP, cut-off concentrations for the diagnosis of acute and chronic HF are respectively 100 and 35 pg/ml [26].

C-type natriuretic peptide

CNP is the most widely expressed NP in the brain and is found in high concentrations in chondrocytes [58,59] and cytokine-exposed endothelial cells [60]. CNP is the most preserved form of NP: both 22- and 53-amino acid versions of CNP are identical in humans, pigs and rats. Human proCNP contains 103 residues and the intracellular endoprotease furin has been shown to process proCNP to the mature 53-amino acid peptide (Figure 1) [61].

In some tissues, CNP-53 is cleaved to CNP-22 by an unknown extracellular enzyme. Although CNP-22 and CNP-53 elicit similar, if not, identical functions [62], their tissue expression differs. CNP-53 is the major form in the brain [63], endothelial cells [64] and heart [65], whereas CNP-22 predominates in human plasma and cerebral spinal fluid [66]. Normal plasma CNP concentrations (both forms) are in the low fmol/ml range and are minimally, if at all, elevated in patients with congestive HF [67]. Therefore, CNP does not behave as a cardiac hormone, although its potential role in HF cannot be ruled out.

Natriuretic peptide receptor

There are three known NP-binding proteins in mammals: NP receptor (NPR)-A, NPR-B and NPR-C (Figure 2). NPR-A and NPR-B represent two of the five transmembrane guanylate cyclases found in humans [68] and determine the biological effects of NP. The third NPR, NPR-C, does not possess any known intrinsic enzymatic activity. Human NPR-A mRNA is highly expressed in kidney, adrenal, terminal ileum, adipose, aortic and lung tissues [69], NPR-B protein has been found at relatively high concentrations in fibroblasts [70]. NP clearance receptor (NPR-C) mRNA is found in atrial, mesentery, placenta, lung, kidney, venous tissue [71] and in aortic smooth muscle and aortic endothelial cells. In situ hybridization studies found detectable NPR-C mRNA in kidney, adrenal, heart, cerebral cortex and cerebellum tissue [72].

Physiological effects of natriuretic peptides

NPs elicit their physiological responses (Table 1) mostly through NPR-A binding and the activation of guanylate cyclase and the production of cGMP, a classic intracellular second messenger [73]. The best-studied cGMP signalling effects occur through protein kinases G (PKG), serine and threonine kinases that are activated by cGMP binding [74].

The ANP/NPR-A coupling regulates basal blood pressure in experimental models. Some of the most striking data on this issue come from the demonstration that ANP-dependent guanylate cyclase activities and blood pressure are directly proportional to NPR-A gene dosage over a range of 0–4 alleles [75]. ANP regulates blood pressure by means of its combined effects on intravascular volume, vasorelaxation, natriuresis and diuresis.

In the kidney, ANP increases glomerular filtration rate (GFR), inhibits sodium and water re-absorption and reduces renin secretion [76]. ANP-dependent diuresis and natriuresis are mediated exclusively by NPR-A in mice because these effects are completely lost in NPR-A knockout animals [77]. ANP increases the GFR by elevating the pressure in the glomerular capillaries through co-ordinated afferent arteriolar dilation and
Natriuretic peptide system and heart failure

Figure 2  Natriuretic peptide-binding receptors, intracellular signalling and degradation processes

Abbreviations: GC-A: guanylate cyclase type A; GC-B: guanylate cyclase type B.

efferent arteriolar constriction [78]. In addition to these effects, ANP inhibits sodium and water re-absorption throughout the nephron. In the proximal tubules, ANP inhibits Ang II-stimulated sodium and water transport [79]. In collecting ducts, it reduces sodium absorption by inhibiting an amiloride-sensitive cation channel [80]. The effect of ANP on both transport processes is cGMP-dependent. ANP/NPR-A coupling appears to be down-regulated in HF and in conditions of RAAS activation and high Ang-II concentrations [81–83].

CNP also is a vasodilator and is released in response to vascular injury [84] NPR-B is present in aortic vascular smooth muscle and mediates CNP relaxation of pre-contracted rat aorta [85]. Furthermore, CNP inhibits vascular smooth muscle proliferation [86] and oxidized low-density lipoprotein-induced migration of cultured human coronary artery smooth muscle cells [87] in a cGMP-dependent manner. CNP may be an endothelium-derived hyperpolarizing factor (EDHF), participating in the paracrine action of other endothelial vasorelaxant mediators, such as nitric oxide (NO) and prostacyclin [88]. CNP may act also through a post receptor intracellular pathway linked to cAMP.

ANP regulates blood pressure, in part, through the inhibition of the RAAS. In dogs, intra-renal ANP infusion markedly inhibits the renin secretion rate [89,90]. In addition to inhibiting renin secretion, ANP directly inhibits aldosterone production in the adrenal glomerulosa (adrenocorticotropic hormone [ACTH]-stimulated, Ang-II-stimulated and basal aldosterone levels) [91,92]. Interestingly, ANP has also been shown to modulate arterial and cardiac baroreflex mechanisms in animal model and in humans. In particular, ANP enhances vagal afferents and blunts sympathetic response [93–95].

ANP and BNP have direct effects on the heart. Mice lacking ANP or NPR-A have enlarged hearts [96], whereas animals overexpressing ANP have smaller hearts [97]. Initially, it was unclear whether the cardiac hypertrophy observed in the knockout animals resulted from prolonged exposure to systemic hypertension or from the loss of a local inhibitory effect on heart growth; it is likely that both processes lead to cardiac hypertrophy. The first evidence supporting a local effect involved NPR-A knockout mice that were treated with anti-hypertensive drugs from birth. These animals were normotensive but still had cardiac hypertrophy [98]. The selective transgenic replacement of NPR-A in the heart of NPR-A knockout animals reduced cardiomyocyte size without affecting hypertension [99]. Pre-clinical data have demonstrated the ability of ANP to inhibit cardiomyocyte hypertrophy induced by either Ang-II or endothelin-1, both vasoactive peptides with deleterious effects on the cardio-renal system.
system, as a result of cGMP-dependent processes [100]. Moreover, ANP may protect against Ang-II-induced cardiac remodelling by minimizing steps that are key to the inflammatory process including macrophage infiltration and expression of pro-inflammatory factors [101]. In vitro evidence indicates that ANP can attenuate norepinephrine-induced growth of cardiac myocytes and fibroblasts due to a cGMP-mediated inhibition of norepinephrine-induced influx of Ca^{2+} [102]. These findings may highlight a key role of the NP system in counteracting the adverse effects of increased SNS activity on the myocardium [94,95]. Finally, mutated forms of ANP are associated with cardiac hypertrophy [103].

All three NPRs are highly expressed in the lung [104]. ANP stimulates the dilation of pulmonary airways and blood vessels. Infusion or inhalation of ANP stimulates bronchodilatation in normal and asthmatic patients [104]. ANP and BNP are elevated in patients with pulmonary hypertension and are indicative of increased right ventricular strain [105]. Mice overexpressing ANP are resistant to hypoxia-induced hypertension, whereas ANP-deficient mice exhibited increased pulmonary hypertension in response to chronic hypoxia [106]. CNP also reduces pulmonary hypertension [107] and fibrosis [108] and this mechanism is thought to be relevant in the progression of HF.

ANP stimulated lipolysis both in isolated human fat cells and in vivo by peptide infusion [109]. It was determined that ANP-stimulated lipolysis is specific to primates, presumably because primates contain a higher NPR-A to NPR-C ratio [110]. PKGI is the cGMP effector in the ANP-dependent lipolytic response because pharmacological inhibition of PKGI decreases ANP-dependent lipolysis in primary human pre-adipocytes [111].

Degradation of natriuretic peptides

All three NPs are degraded through two main processes (Figure 2): (1) NPR-C-mediated internalization followed by lysosomal degradation and (2) enzymatic degradation by neutral endopeptidase 24.11 or nephrilysin (NEP), a zinc-dependent enzyme expressed on the plasma membrane that has broad substrate specificity and tissue distribution [112].

The reported half-life of ANP ranges from 0.5 to 4 min in mice, rats, rabbits, dogs and monkeys [113] and is approximately 2 min in normal human subjects [114,115]. Most tissues remove ANP from the circulation, but some organs are more efficient at ANP extraction than others. Early human studies indicated that approximately 30%–50% of ANP is removed by the kidney, liver or lower limbs, whereas no extraction was observed across the lung [116,117]. However, later reports in humans and dogs indicated that the lungs have a significant ANP extraction rate of between 19% and 24%. The organ preference for ANP extraction is lung > liver > kidney [118].

Few studies have addressed the clearance of BNP and CNP. The removal of BNP from the human circulation recognized short and long half-life components of 3.9 and 20.7 min respectively [52], BNP binds to human NPRC 7% as tightly as ANP and the increased half-life of BNP results from decreased removal by NPRC-mediated internalization and degradation [119].

NPR-C-mediated ANP clearance was first demonstrated by Maack et al. in 1987 [120]. The cellular mechanics of NPRC-mediated NP internalization and degradation are similar to those of the receptors for low-density lipoprotein and hyaluronic acid. Similar features include lysosomal ligand hydrolysis and recycling of the ligand-free receptor back to the plasma membrane. Internalization is speculated to occur through a clathrin-dependent mechanism, but this has not been demonstrated. NPs are also degraded by extracellular proteases (Figure 2). NEP, the most important one, was initially discovered in rabbit kidney brush border membranes as a metalloenzyme that degrades the insulin β-chain [121] and subsequently as an enkephalinase and β-amylloid-degrading enzyme [122]. NEP is a zinc-containing, membrane-bound, ectoenzyme that cleaves substrates on the amino side of hydrophobic residues [121]. ANP-degrading activity in solubilized rat membranes co-purifies with NEP and is blocked by specific NEP inhibitors [123].

Purified NEP binds and degrades NPs similarly to other peptide hormones such as Ang-II [124]. Seven ANP cleavage sites were identified, but the initial attack occurs between Cys2 and Phe6, breaking the ring and inactivating the peptide [125]. NEP also efficiently cleaves CNP at multiple sites and, as with ANP, the initial cleavage site is between the conserved cysteine and the phenylalanine residues [126]. The ring structures of both ANP and CNP are essential for hydrolysis, because reduction and alkylation of the peptides greatly reduced degradation. In contrast with ANP or CNP, which have one or zero amino acid differences between human and rodent forms, BNP varies greatly among species [127]. Studies with purified enzymes indicated that BNP is a poorer substrate for human or porcine NEP than ANP or CNP. NEP cleaves human BNP at M7-V6 and R17-I38, but not at the conserved C109.F11 bond [128]. NEP-dependent degradation of BNP is species-specific. Although NEP accounts for most of the BNP-degrading activity in rat kidney membranes, NEP inhibitors failed to block BNP degradation by human kidney membranes, suggesting that NEP is not a significant regulator of BNP concentrations in the human kidney [129,130].

ANP is also cleaved by insulin-degrading enzyme (IDE), a zinc metalloprotease that is found in both cytoplasmic and membrane fractions and has diverse substrate specificity [131] (Figure 2). On the basis of competition with insulin for ANP degradation and a partial amino acid sequence of the 112-kDa protein, IDE was suggested to be an ANP-degrading enzyme [132]. Proteolysis of rat ANP, porcine BNP-26 and CNP with purified IDE revealed that ANP is the preferred substrate [133].

The relative contributions of NPR-C and NEP to ANP degradation have been investigated in a number of animal systems, with various NPR-C-blocking peptides and NEP inhibitors. Under normal conditions, infusion of NPR-C-blocking peptides has an effect on circulating ANP concentrations and associated physiological functions that is slightly greater than or equal to that of various NEP inhibitors [134–137]. However, in all cases examined, maximum ANP concentrations require inhibition of both degradation pathways. In pathological or pharmacological scenarios where ANP concentrations are elevated and NPR-C may be saturated, NEP plays a more significant role in ANP degradation [138]. Both NPR-C and NEP pathways contribute to the degradation of BNP and CNP as well, although the exact
contribution of each pathway to BNP concentrations is unclear [129]. NEP inhibition reduced CNP clearance by the kidney but not the lung, suggesting that NEP significantly contributes to CNP degradation in some but not all tissues.

THE NATRIURETIC PEPTIDE SYSTEM IN HEART FAILURE

Congestive HF is a complex syndrome characterized by sodium and water retention. A decrease in cardiac output and effective intra-arterial volume leads to renal retention of sodium and water despite expansion of the extracellular fluid volume. This phenomenon occurs in the presence of a progressive activation of the NP system [139]. However, this response is apparently insufficient to counteract the activation of vasoconstriction and sodium retention of RAAS and SNS [140,141].

Several clinical and experimental studies have implicated both ANP and BNP in the pathophysiology of the deranged cardiorenal axis in HF. Early studies have shown that ANP release in response to acute volume overload or chronic salt loading are impaired in asymptomatic patients with cardiomyopathy and LV dysfunction [4,142]. This impairment of ANP adaptation to volume challenge in the early stages of HF is associated with blunted natriuretic, vasodilator and renin–aldosterone suppressing actions. Therefore, this hormonal abnormality may play a role in the progression of sodium retention and vasoconstriction in HF. It is interesting that pre-treatment with RAAS-inhibiting drugs, such as ACE inhibitors, may partially restore the ANP secretagogue response to volume expansion in HF [126] and that pre-treatment with an ARB may preserve the natriuretic and renal vasodilating capacity of ANP in the same condition [5].

Although initially considered to be a state of ANP deficiency, it soon became evident that in HF plasma levels of ANP are systematically elevated and positively correlated with the severity of the disease, as well as with the elevated atrial pressure and other parameters of LV dysfunction [143]. The highest concentrations of ANP in the circulation occur in advanced stages of HF and the high levels of plasma ANP are attributed to increased right-sided heart production rather than to decreased clearance. Although volume-induced atrial stretch is the main source for the elevated circulating ANP levels in HF, enhanced synthesis and release of the hormone by the ventricular tissue in response to Ang-II and endothelin contribute to this phenomenon [144,145]. Vagal stimulation linked to circulatory baroreflex control or to cardiac mechanoreceptor modulates ANP production and release from the heart [94,140,141]. As mentioned above, even the highest levels of circulating NPs due to massive cardiac secretion in advanced end stage congestive HF may indeed be insufficient to counteract the over-stimulation of the anti-natriuretic and vasoconstrictive neurohormonal system (SNS and RAAS) thus characterizing HF as a state of neurohormonal imbalance. Moreover, this has also been observed in models characterized by overstimulation of RAAS or high levels of Ang-II [146].

Despite the high levels of this potent natriuretic and diuretic agent, patients and experimental animal models with HF retain salt and water due to attenuated renal responsiveness to NP. In patients with HF [147] and in dogs with HF [148], ANP acts as a counter-regulatory hormone to SNS, RAAS and vasopressin. Infusion of pharmacological doses of synthetic ANP to experimental animals [149] and also to patients with HF [150] has consistently demonstrated an attenuated renal response compared with normal control subjects. This could be linked to a down-regulation of NP receptors in a condition of overstimulation of RAAS [81–83]. However, other beneficial effects accompany the infusion of ANP to patients with HF, such as haemodynamic improvement and inhibition of activated neurohumoral systems [151]. In fact, despite the blunted renal response to ANP in HF, elimination of this peptide by surgical means aggravates the activation of these vasoconstrictive hormones in this disease state. For instance, elimination of ANP source in dogs with HF due to rapid pacing by atrial appendectomy resulted in substantial increments in plasma renin activity and plasma norepinephrine, as well as marked sodium and water retention [152]. The activation of these systems was less profound in dogs with HF that did not undergo appendectomy, suggesting that ANP plays a critical role as a suppressor of sodium-retaining systems. Therefore, the increase in circulating NP, albeit insufficient to preserve sodium and water balance, is still considered an important adaptive or compensatory mechanism aimed at reducing peripheral vascular resistance and effective blood volume. The initial chronic phase of HF, which is characterized by sodium balance despite cardiac dysfunction, has been attributed to the elevated levels of ANP and BNP [153].

This notion is supported by the findings that inhibition of NPR in experimental HF induces sodium retention [154]. Furthermore, NPs inhibit the systemic vasoconstrictive effect of Ang-II [155], Ang-II-stimulated proximal tubule sodium re-absorption [156], Ang-II-enhanced secretion of aldosterone and the secretion of endothelin [157]. Therefore, NPs in HF act as an ideal counter-regulatory mechanism, influencing renal blood flow (RBF) and sodium excretion either through their direct renal actions or through inhibition of release or action of other vasoconstrictive agents. Moreover, beside these cardiovascular and endocrine effects, NPs probably play an important role in promoting salt and water excretion by the kidney in HF. Indeed, studies in an experimental model of HF have demonstrated that inhibition of the NP by either specific antibodies to their receptors or the NPR-A antagonist HS-142-1 causes further impairment in renal function, as expressed by increased renal vascular resistance and decreased GFR, RBF, urine flow, sodium excretion and activation of the RAAS [158].

Moreover, the unexpectedly small physiological responses to the apparently high levels of BNP previously observed in patients with HF may be because most of the BNP detected using conventional diagnostic assays is less biologically active. Consequently, HF may in fact represent a deficient state of biologically-active NP. The raised levels of biologically-inactive BNP detected in chronic HF may reflect a potential abnormality in the processing of NP, leading to a deficiency of mature BNP [159]. The increased expression of myocardial NEP mRNA in patients with HF, leading to an accelerated degradation of NPs, supports the hypothesis that a deficiency of NP may be present in HF [160].
The fact that the NP system plays a favourable role, countering the adverse effects of sodium-retaining and vasoconstrictive hormonal systems in HF, provides a rationale for the use of these peptides as therapeutic tool in this disease. Thus, either increasing the activity of the NP or reducing the influence of the anti-natriuretic systems by pharmacological means may achieve a favourable shift in the balance of sodium excretion and vasodilation in HF. In the interplay between the RAAS and ANP in HF, the approaches used in experimental and clinical medicine have included the decrease in the activity of the RAAS by means of ACE inhibitors, ARBs and MRA or increasing the activity of ANP or its second messenger, cGMP or a combination of both approaches.

EXPLORING PHARMACOLOGICAL APPROACHES TO ENHANCE NATRIURETIC PEPTIDE EFFECTS IN HEART FAILURE

We discuss now previous pharmacological attempts to modulate NP in humans and, particularly, to develop new tools to exploit the theoretical advantages of raising NPs in HF.

Exogenous natriuretic peptides and analogues

The first obvious strategy was based on exogenous NP or analogues administration. In fact, intravenous administration of ANP to patients with acute HF improved their clinical status [153]. Carperitide, a human recombinant form of NP, was approved as an intravenous agent for the treatment of acute decompensated HF [127]. However, the short half-life restricted its routine use, prompting the development of novel forms of ANP that are more resistant to enzymatic degradation compared with both native and recombinant forms.

M-ANP is a 40-amino acid peptide consisting of the native 28-amino acid ANP with a 12-amino acid extension to the C-terminal. The extended C-terminal of M-ANP provides greater resistance, compared with native ANP, to NEP and IDE degradation and does not impair binding to NPR-A and cGMP generation [161]. In vivo studies in canines demonstrated that M-ANP possesses a greater blood pressure lowering effect than ANP. It also augments RBF and GFR (despite reductions in blood pressure), promotes natriuresis and diuresis and suppresses RAAS [161].

Recently, in a canine model of HF and acute vasoconstrictive hypertension, M-ANP was shown to possess an acute vasodilator effect similar to nitroglycerin; unlike nitroglycerin, M-ANP improves renal function through significant increases in RBF and GFR and inhibits aldosterone activation [162]. Based on these experimental results, M-ANP has now entered a clinical development programme for further testing.

Nesiritide, a recombinant form of human BNP, has been shown to decrease pulmonary capillary wedge pressure, to provide improvements in the global clinical status reducing dyspnoea and fatigue compared with placebo [163]. Nesiritide was approved for the treatment of acute decompensated HF in the USA in 2001 [127]. Subsequent reports of an increased risk of worsening renal function and death compared with control therapy raised doubts on its safety [164]. The Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF) trial demonstrated that nesiritide had no impact on the rate of death, nor was it associated with worsening renal function [165]. However, nesiritide was associated with increased rates of hypotension. Together with its short bioavailability, this may represent a limitation for the routine use of the drug in clinical practice [165,166].

Cenderitide–NP (CD–NP), is formed by the fusion of native human CNP with a C-terminal sequence of dendroaspis NP (DNP) found in snake venom [167]. CD–NP is less susceptible to degradation by NEP than native NPs [168]. In a canine model, CD–NP elicited potent natriuretic and diuretic responses, increased GFR, inhibited renin and induced less hypotension than BNP. The anti-fibrotic actions of CD–NP have been demonstrated in vivo in an experimental rat model of early cardiac fibrosis [169]. In patients with chronic HF, subcutaneous infusion of CD–NP has previously been shown to provide a dose-dependent reduction in systolic blood pressure and to be well tolerated [170]. CD–NP is currently undergoing phase II clinical trials for chronic therapy in patients with post-acute HF. CU–NP, an alternative version of CD–NP, is constructed using a core component of native human CNP and the C- and N-terminal of urodilatin, a NP of renal origin that predominantly interacts with the NPR-A [171]. Preliminary in vivo data in a canine model have suggested that CU–NP may mediate beneficial cardiac and renal effects, reducing pulmonary capillary wedge pressure and right atrial pressure, inducing natriuresis, increasing GFR and suppressing RAAS [172].

Neprilysin inhibition in treatment of heart failure

A second, more sound strategy is based on the pharmacological enhancement of endogenous NP level. Although this effect can be obtained by blocking clearance NPR receptors or by the inhibition of IDE, the pharmacological approach more frequently used in experimental models and in humans is represented by NEP inhibition.

In evaluating the clinical effects of NEP inhibition it is necessary to consider that in addition to the NP, NEP has many other substrates [173,174], with biological conflicting activity on vascular smooth muscle cell tone and renal excretion of sodium and water, including Ang-I [175], Ang-II [176], kinin peptides, substance P, adrenomedullin, endothelin, chemotactic peptide, enkephalins and the amyloid-β (Aβ) peptide [177]. NEP may also contribute to the formation of endothelin from its precursor big endothelin, although endothelin-converting enzyme (ECE) probably plays a more important role in endothelin formation [178].

For patients with HF, of particular importance are the effects of NEP inhibition on RAAS and kinin peptides, systems that are also modulated by ACE-inhibitors (Figure 3A).

NEP inhibition may increase levels of the vasoconstrictor Ang-II and reduce levels of the vasodilator Ang-(1–7) [179]. In addition, both animal and clinical studies show that NEP inhibition impairs the metabolic clearance of Ang-II and increases plasma levels of Ang-I, Ang-II, aldosterone and catecholamines [180,181].

Moreover, NEP plays a major role in the metabolism of kinin peptides [182] and increased urinary kinin peptide levels may
contribute to the natriuretic effects of NEP inhibition [183]. Kinins may also mediate the cardiac effects of NEP inhibition. NEP inhibition impairs kinin metabolism in the heart [181] and kinin receptor antagonism prevents the protective effects of NEP inhibition in animal models of ischaemia-reperfusion injury in the heart [184, 185] and in isoproterenol-induced myocardial hypoperfusion [186]. Finally, since NEP is involved in the degradation of the Aβ peptides, which are implicated in the development of Alzheimer’s disease, concerns have been raised that NEP inhibition might produce an accumulation of Aβ peptides in plaque-like deposits in the brain [187], although studies up to 5 years of follow-up have not supported this concern. Despite the favourable expectation related to the enhancement of the NP effects obtained through inhibition of NEP, clinical results obtained with multiple pharmacological intervention strategies used in the past have not prompted favourable clinical results in patient with HF, probably due to the concomitance of the effects that the inhibition of NEP induces on other systems [179], particularly RAAS and the kinin system.

Neprilysin inhibitors
The effects on blood pressure of a NEP inhibitor alone are quite variable. There may be no change, a decrease or an increase in blood pressure of normotensive and hypertensive human subjects in response to NEP inhibition [188–190].

The variable effect of NEP inhibition on blood pressure and systemic vascular resistance is likely to be related to the multiple actions of NEP on many different vasoactive peptides. Increased blood pressure during candoxatril treatment, a pure NEP inhibitor, in healthy volunteers was associated with an increase in plasma Ang-II and endothelin levels [191]. In hypertensive patients candoxatril did not produce clinically favourable effects [192] probably because the negative haemodynamic effects linked to activation of RAAS counteracted the positive effects related to raising NP (Figure 3B). Also, in patients with HF, the haemodynamic effects of candoxatril were not favourable, with an increase in peripheral vascular resistance and a stroke volume decrease [193].

As a result of neutral or negative clinical data obtained in hypertensive patients and, in HF, the clinical use of a NEP inhibitor alone was discouraged.

Taking together, the overall complex biological effects due to NEP inhibition and the unfavourable results obtained in the past, it was reasonable to try different strategies, such as NEP inhibitors, NEP inhibitors associated with an ACE inhibitor or vasopeptidase inhibitors.

Neprilysin inhibitors associated with an angiotensin-converting enzyme inhibitor
Addition of NEP inhibition to ACE inhibition produced indeed greater inhibition of bradykinin metabolism and higher
bradykinin levels than those seen with either ACE or NEP inhibition alone [176]. The increased kinin peptide levels may contribute to the natriuretic, hypotensive and cardioprotective effects of addition of NEP inhibition to ACE inhibition. However, given the recognized role of kinin peptides in ACE inhibitor-induced angioedema [194, 195] the additional downgrading of kinin metabolism by NEP inhibition would be predicted to increase the occurrence of angioedema. In addition, by increasing Ang-II levels and reducing Ang-(1–7) levels NEP inhibition may counteract any benefit of ACE inhibition that depends on reduced Ang-II levels and increased Ang-(1–7) levels.

Despite the potential advantages of the association between ACE inhibitor and NEP inhibitor, the clinical results obtained have not confirmed any usefulness of this therapeutic approach.

In particular, for patients with HF, the addition of the NEP inhibitor ecdotril to standard therapy, including ACE inhibition, produced no evidence of improvement in signs or symptoms [196]. Of particular concern was the occurrence of aplastic anemia in several patients, which was attributed to the thioester group on the ecdotril molecule [197]. As a result of non-positive clinical data obtained, also this pharmacological option was abandoned.

**Vasopeptidase inhibitors**

Several dual ACE/NEP inhibiting molecules have been developed [198–200]. In assessing the results obtained with the so called vasopeptidase inhibition it is important to consider that the separate titration of ACE and NEP inhibition is not possible when both are mediated by a single molecule because the ratio of ACE to NEP inhibition is fixed (Figure 3C). It is therefore important to assess whether dual ACE/NEP inhibitors have therapeutic effects different from ACE inhibition alone.

The most extensively investigated dual ACE/NEP inhibitor was omapatrilat (BMS-186716). The initial experience with this compound was very promising, due to its potent blood pressure lowering effect. Then omapatrilat was tested in HF. In the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERSTUDY) study E5770 patients with New York Heart Association (NYHA) class II–IV HF were randomized to treatment with either enalapril [10 mg twice daily (BID)] or omapatrilat (40 mg once daily) for a mean of 14.6 months [201]. Enalapril or omapatrilat were added to conventional therapy that included β-blockers in 50% of patients. The primary end-point of combined risk of death or hospitalization for HF requiring intravenous treatment was not different for the two treatment groups. A reasonable explanation for the failure of omapatrilat to produce obvious advantages compared with ACE inhibitor was the short duration of NEP inhibition produced by this compound [202]. Although it may be argued that a higher dosage or BID dosage may have increased the benefits obtained with omapatrilat in HF, it could also be claimed that a higher dosage of enalapril may similarly increase the benefits from ACE inhibition alone. Angioedema was reported in similar proportions of omapatrilat-treated (0.8%) and enalapril-treated patients (0.5%). The slightly higher incidence of angioedema especially in the Afro-American population raised concerns and was shown later to be more relevant in hypertensive patients. In the OCTAVE study [203], angioedema was reported in 2.2% of patients receiving omapatrilat and in 0.7% of patients receiving enalapril. The high rate of angioedema in hypertensive patients and the non-superiority compared with ACE inhibitor in patients with HF led to the interruption of the clinical development of omapatrilat.

**Angiotensin receptor neprilysin inhibition and ARB combination with LCZ696 (sacubitril/valsartan) compound**

Quite recently, a novel pharmacological approach based on the combination of Ang receptor NEP inhibitor (ARNI) has been developed with the rational to generate a novel tool to target NP enhancement and RAAS blockade without increasing side effects, thus overcoming the drawbacks and failures encountered with the strategies described above (Figure 3D).

LCZ696, a first-in-class ARNI, comprises molecular moieties of valsartan, a well-established ARB [204] and of the NEP inhibitor produg sacubitril (AHU377), which is metabolized to the active NEP inhibitor LBQ657 by enzymatic cleavage of its ethyl ester [205]. LCZ696 is a novel single molecule in which the molecular moieties of valsartan and the molecular moieties of AHU377 are present in a 1:1 molar ratio. Pre-clinical studies in rats and dogs, performed by the producer and reported in the Investigator Brochure, demonstrated that inhibition of NEP enzyme activity and the AT1 (Ang II receptor type 1) receptor through LCZ696 increase the levels and effects of ANP while blocking the actions of Ang-II. This produces dose-related and long-lasting vasodilatory effects after single and multiple oral administrations, along with beneficial and protective effects on renal, vascular and cardiac tissue in rat models of hypertension, myocardial infarction and organ injury.

The bioavailability studies demonstrated that systemic exposure to valsartan following a single 400 mg of oral dose of LCZ696 was equivalent to that following administration of 320 mg of valsartan, a dose that has proven anti-hypertensive efficacy in clinical trials [166]. Analysis of dose-normalized pharmacokinetic data from either pre-clinical or clinical studies showed that the exposure of valsartan following administration of LCZ696 was approximately 40% higher than the exposure following administration of valsartan alone.

Inhibition of NEP activity increases levels of ANP, which in turn stimulates the synthesis of cGMP via guanylate cyclase-linked receptors. Pre-clinical pharmacodynamic studies demonstrated a rapid and dose-dependent increase in plasma ANP immuno-reactivity following oral administration of LCZ696, whereas multiple-dose administration of LCZ696 in the dose escalation study in healthy participants significantly increased plasma cGMP levels [206]. These findings are consistent with inhibition of NEP activity.

LCZ696 stimulated significant dose-dependent increases in renin concentration, plasma renin activity and Ang-II concentration compared with placebo, indicative of blockade of the AT1 receptor by LCZ696. Notably, LCZ696 (200 mg) increased renin concentration by 3.1-fold, plasma renin activity by 4.9-fold and Ang-II by 3.7-fold relative to placebo. These increases are of a similar order of magnitude to those observed previously with administration of valsartan 320 mg in healthy participants.
Figure 4  Current therapeutic approaches for HF and the novel role of ARNI

- **β-blockers**
- **Vasodilators and diuretics**
- **RAAS inhibitors**

**SNS**
- Vasoconstriction
- RAAS activity
- Vasopressin
- Heart rate
- Contractility

**HF symptoms & progression**

**NP system**

**RAAS**
- Vasoconstriction
- Sodium retention
- Blood pressure
- Sympathetic tone
- Aldosterone
- Fibrosis
- Hypertrophy

**Angiotensin receptor nepriylisin inhibitor (ARNI)**

An enlarged left atrium is a characteristic finding in patients with HFrEF and it reflects sustained increases in LV filling pressures. These parameters were significantly reduced from baseline to a greater extent in patients treated with LCZ696 compared with those treated with valsartan, thus indicating reverse left atrial remodelling. The tolerability profile of LCZ696 was satisfactory and similar to that of valsartan.

The effect of LCZ696 on outcomes compared with enalapril in patients with HFrEF (heart failure with reduced ejection fraction) was evaluated in the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure (PARADIGM-HF) trial [210]. Eligibility requirements at screening included an age of at least 18 years, NYHA class II, III or IV and an ejection fraction of 35% or less. Patients were required to have a plasma BNP level of at least 150 pg/ml (or an NT-proBNP level ≥ 600 pg/ml) or, if they had been hospitalized for HF within the previous 12 months, a BNP of at least 100 pg/ml (or an NT-proBNP ≥ 400 pg/ml). Patients taking any dose of an ACE inhibitor or ARB were considered for participation, but for at least 4 weeks before screening, patients were required to take a stable dose of a β-blocker and an ACE inhibitor (or ARB) equivalent to at least 10 mg of enalapril daily.

Patients eligible were randomly assigned in a 1:1 ratio to double-blind treatment with either enalapril (at a dose of 10 mg BID) or LCZ696 (at a dose of 200 mg BID).
The primary outcome was a composite of death from cardiovascular causes or a first hospitalization for HF. The secondary outcomes were the time to death from any cause, the change from baseline to 8 months in the clinical summary score on the Kansas City Cardiomyopathy Questionnaire (KCCQ) [211], the time to a new onset of atrial fibrillation and the time to the first occurrence of a decline in renal function.

Patients (4187) were randomly assigned to receive LCZ696 and 4212 to receive enalapril for the intention-to-treat analysis. Death from cardiovascular causes or hospitalization for HF (the primary end point) occurred in 914 patients (21.8%) in the LCZ696 group and 1117 patients (26.5%) in the enalapril group [hazard ratio in the LCZ696 group, 0.80; 95% confidence interval (CI), 0.73–0.87; P < 0.001 (exact P = 4.0 × 10⁻⁷)]. The difference in favour of LCZ696 was seen early in the trial and at each interim analysis. A total of 558 deaths (13.3%) in the LCZ696 group and 693 (16.5%) in the enalapril group were due to cardiovascular causes (hazard ratio, 0.80; 95% CI, 0.71–0.89; P = 0.001). Of the patients receiving LCZ696, 537 (12.8%) were hospitalized for HF, as compared with 658 patients (15.6%) receiving enalapril (hazard ratio, 0.79; 95% CI, 0.71–0.89; P < 0.001).

A total of 711 patients (17.0%) in the LCZ696 group and 835 patients (19.8%) in the enalapril group died (hazard ratio for death from any cause, 0.84; 95% CI, 0.76–0.93; P < 0.001). The effect of LCZ696 was consistent across all pre-specified representative population sub-groups.

The mean change from baseline to month 8 in the KCCQ clinical summary score was a reduction of 2.99 points in the LCZ696 group and a reduction of 4.63 points in the enalapril group (between-group difference, 1.64 points; 95% CI, 0.63–2.65; P = 0.001).

Patients in the LCZ696 group were more likely than those in the enalapril group to have symptomatic hypotension, but these events rarely required the discontinuation of treatment. In contrast, cough, a serum creatinine level of 2.5 mg/dl (221 μmol/l) or more and a serum potassium level of more than 6.0 mmol/l were reported less frequently in the LCZ696 group than in the enalapril group (P < 0.05 for all comparisons). There were no statistically significant differences between LCZ696 and enalapril in the incidence of angioedema (global non-hospitalized plus hospitalized 0.4% compared with 0.3% respectively) and, in particular, there were no cases in either group which resulted in airway compromise. Fewer patients in the LCZ696 group than in the enalapril group stopped their study medication because of an adverse event (10.7% compared with 12.3%, P = 0.03) or because of renal impairment (0.7% compared with 1.4%, P = 0.002).

In conclusion, LCZ696 was superior to ACE inhibition at recommended doses in reducing the risks of death and of hospitalization for HF. The magnitude of the beneficial effect of LCZ696, as compared with enalapril on cardiovascular mortality, was at least as large as that of long-term treatment with enalapril, as compared with placebo (Figure 5). According to a secondary analysis, LCZ696 prevented the clinical deterioration or progression of surviving patients in terms of required treatment intensification of therapy, hospital visits or admissions and use of advanced management modalities (inotropes, assist devices, transplantation) more effectively than did enalapril. Moreover, levels of both urinary cGMP and plasma BNP were higher during treatment with LCZ696 than with enalapril, reflecting the fact that the peptides, whose levels are enhanced by NEP inhibition, are active and bind receptors leading to enhancement of cGMP. In contrast, in comparison with enalapril, patients receiving LCZ696 had consistently lower levels of NT-proBNP (reflecting reduced cardiac wall stress) throughout the trial. The divergent effects of LCZ696 on the two types of NPs can be explained by the fact that BNP (but not NT-proBNP) is a substrate for NEP; thus, levels of BNP will reflect the action of the drug, whereas levels of NT-proBNP will reflect the effects of the drug on the heart [212]. On the basis of these results, LCZ696 has been recently approved by the Food and Drug Administration (FDA) for the treatment of HFpEF; trade name is Entresto (http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm453845.htm).

The potential clinical relevance of these data is evident and these results may represent a new standard of treatment threshold for patients with HF [213]. However the extent of clinical benefits obtained with LCZ696, in many ways unexpected, at least for the observed size, poses questions about the biological plausibility of the results, which must be answered also in relation to previous experiences of pharmacological modulation of the NP system in patients with HF.

In spite of the obvious biological plausibility of the effects of LCZ696 on the NP system and RAAS in HF to explain the beneficial clinical findings, further work will be required to investigate these aspects in deeper detail. Among the various potential mechanisms that have been discussed after the publication of PARADIGM-HF, it seems unlikely, based on the previous clinical comparison between ACE inhibitors and ARBs that the benefits of LCZ696 are due to the ARB component of the ARNI by itself. In fact, in ELITE (Evaluation of Losartan in the Elderly study), VALIANT (VALsartan In Acute myocardial infarction), VAL-HEFT (Valsartan Heart Failure Trial) and CHARM (Can desartan in Heart failure - Assessment of moRtality and Morbidity) [14,214–217], ARB were never superior to ACE inhibitors. For similar reasons, a fundamental role of the NEP inhibitor acting as a diuretic added to the ARB can be excluded. The role
of increased NP levels in the blood by itself also does not seem to represent a reasonable mechanism, in view of the negative results on outcomes of NEP inhibitors and vasopeptidase inhibitors. Nonetheless, it may be important that the presence of higher levels of NP are able to bind NPR-A receptors and to produce the biological response. In this regard, a role could also be played by a greater availability of NPR-A to be coupled by higher active NP and activate the guanylate cyclase pathway with a higher production of cGMP, which appears indeed to be the case in a sub-population of the PARADIGM-HF in which urinary cGMP was measured and indeed it was selectively increased in the group treated with LCZ696 [218]. The concomitant blockade of RAAS by the ARB valsartan may have partially antagonized the NPR-A down-regulation described in HF, given the interactions between the Ang-II and NP intracellular signalling pathways [219–222]. Finally, a role of the blood pressure lowering effect of LCZ696 cannot be completely ruled out, which may unload the heart and produce clinical benefits. In this regard, the blockade of the AT-1 receptor, which counteracts the increase in Ang-II due to NEP inhibition, by the concomitant ARB may play a relevant role.

Further studies are ongoing to analyse the clinical effects of LCZ696 in patients with HFrEF and HfPEF. The Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction (PARAGON-HF) is a multicentre, randomized, double-blind, controlled clinical study with the aim to evaluate the effect of LCZ696 compared with valsartan in reducing the rate of the composite end-point of CV death and total (first and recurrent) HF hospitalizations in patients with HfPEF and NYHA class II–IV. Secondary outcomes are cumulative number of events of the extended composite end-point of CV death, total HF hospitalizations, total non-fatal strokes and total non-fatal myocardial infarctions, change from baseline to month 5 in NYHA functional class, time to new onset of atrial fibrillation and time to all-cause mortality (https://clinicaltrials.gov/ct2/show/NCT01920711).

In addition, LCZ696 has been investigated in comparison with olmesartan in patients with resistant hypertension, focusing on the effects on central blood pressure (PARAMETER study) [223].

CONCLUSION

HF is a syndrome characterized by the activation of different neurohormonal systems such as SNS, RAAS and NP. So far, the therapeutic approach has been based on pharmacological interventions to down-modulate RAAS, through ACE inhibitors [193,196,201], ARBs and MRA and SNS through β-blockers. In the last years, more attention has been paid to potential advantages linked to the system of NP.

After the negative results of the study with NEP inhibitors, alone or associated with an ACE inhibitor and vasopeptidase inhibitors [193,196,201], recently, extremely encouraging results have been obtained with the new pharmacological class of Ang receptor and NEP inhibitor, currently defined ARNI. Indeed, LCZ696 produced a remarkable reduction in morbidity and mortality compared with optimal treatment of HF including enalapril up to a degree similar to that determined by the ACE inhibitors when compared with placebo. The new pharmacological approach to manage HF, supported by the results of PARADIGM-HF, may prompt a conceptual shift in the treatment of HF, moving from the inhibition of RAAS and SNS to the targeting of a neuro-hormonal re-balancing in HF. Further studies are ongoing to analyse the clinical effects of LCZ696 in patients with HFrEF and in patients with HfPEF (PARAGON-HF).

REFERENCES

1. Francis, G.S., Benedict, C., Johnstone, D.E., Kirlin, P.C., Nicklas, J., Liang, C.S., Kubo, S.H., Rudin-Toretsky, E. and Yusuf, S. (1990) Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 82, 1724–1729 CrossRef PubMed
2. Francis, G.S., McDonald, K.M. and Cohn, J.N. (1993) Neurohormonal activation in preclinical heart failure: remodeling and the potential for intervention. Circulation 87 Suppl. IV, IV-90–96
3. Benedict, C.R., Shelton, B., Johnstone, D.E., Francis, G., Greenberg, B., Konstam, M., Probstfield, J.L. and Yusuf, S. (1996) Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. Circulation 94, 690–697 CrossRef PubMed
4. Volpe, M., Titto, C., De Luca, N., Mele, A.F., Lembo, G., Rubattu, S., Romano, M., De Campra, P., Enea, I., Ricciardelli, B. et al. (1991) Failure of atrial natriuretic factor to increase with saline load in patients with dilated cardiomyopathy and mild heart failure. J. Clin. Invest. 88, 1481–1489 CrossRef PubMed
5. Magri, F., Ruo, M.A., Cangianiello, S., Bellizzi, V., Russo, R., Mele, A.F., Andreucci, M., Memoli, B., De Nicola, L. and Volpe, M. (1998) Early impairment of renal hemodynamic reserve in patients with asymptomatic heart failure is restored by angiotensin II antagonism. Circulation 98, 2849–2854 CrossRef PubMed
6. Mastromarino, V., Volpe, M., Musumeci, M.B., Autore, C. and Conti, E. (2011) Erythropoietin and the heart: facts and perspectives. Clin. Sci. 120, 51–63 CrossRef PubMed
7. Sharpe, D.N., Murphy, J., Coxon, R. and Hannan, S.F. (1984) Enalapril in patients with chronic heart failure: a placebo-controlled, randomized, double-blind study. Circulation 70, 271–278 CrossRef PubMed
8. Captopril-Digoxin Multicenter Research Group (1988) Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure. JAMA 259, 539–544 CrossRef PubMed
9. Captopril Multicenter Research Group (1983) A placebo-controlled trial of captopril in refractory chronic congestive heart failure. J. Am. Coll. Cardiol. 2, 755–763 CrossRef PubMed

© 2016 The Author(s) This is an open access article published by Portland Press Limited and distributed under the Creative Commons Attribution License 3.0
10 Le Jemtel, T.H., Keung, E., Frishman, W.H. and Ribner, H.S. (1982) Hemodynamic effects of captopril in patients with severe heart failure. Am. J. Cardiol. 49, 1484–1488 CrossRef PubMed

11 SOLVD Investigators (1991) Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N. Engl. J. Med. 325, 293–302 CrossRef PubMed

12 Jong, P. and Yusuf, S. (2002), Extended follow-up of the Studies of Left Ventricular Dysfunction (SOLVD) prevention and treatment trials. European Society of Cardiology Meeting, Berlin, Germany, 31 August–4 September 2002

13 Cohn, J.N. and Tognoni, G. (2001) A randomized trial of the ACE-inhibitor, angiotensin II receptor antagonist and aldosterone antagonist in patients with chronic heart failure. N. Engl. J. Med. 345, 1667–1675 CrossRef PubMed

14 Pfeffer, M.A., Swedberg, K., Granger, C.B., Held, P.; McMurray, J.J., Michelson, E.L., Olofsson, B., Ostergren, J., Yusuf, S. and Pocock, S. (2003) Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARMI-Overall programme. Lancet 362, 759–766 CrossRef PubMed

15 McMurray, J.J., Oster, J., Swedberg, K., Granger, C.B., Held, P., Michelson, E.L., Olofsson, B., Yusuf, S. and Pfeffer, M.A. (2003) Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 362, 767–771 CrossRef PubMed

16 Yusuf, S., Pfeffer, M.A., Swedberg, K., Granger, C.B., Held, P., McMurray, J.J., Michelson, E.L., Olofsson, B. and Ostergren, J. (2003) Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 362, 777–781 CrossRef PubMed

17 Pitt, B., Zannad, F., Remme, W.J., Cady, R., Castaigne, A., Perez, A., Palensky, J. and Witzes, J. (1999) Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N. Engl. J. Med. 341, 709–717 CrossRef PubMed

18 Pitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S., Kleinman, J. and Gatlin, M. (2003) Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 348, 1309–1321 CrossRef PubMed

19 Zannad, F., McMurray, J.J., Drexler, H., Krum, H., Van Veldhuisen, D.J., Swedberg, K., Shi, H., Vincent, J. and Pitt, B. (2010) Rationale and design of the Eplerenone in Mild Patients Hospitalization And Survival Study in Heart Failure (EMPHASIS-HF). Eur. J. Heart Fail. 12, 617–622 CrossRef PubMed

20 Zannad, F., McMurray, J.J., Krum, H., Van Veldhuisen, D.J., Swedberg, K., Shi, H., Vincent, J., Pocock, S.J. and Pitt, B. (2011) Eplerenone in patients with systolic heart failure and mild symptoms. N. Engl. J. Med. 364, 11–21 CrossRef PubMed

21 Hjalmarson, A., Goldstein, S., Fagerberg, B., Wedel, H., Waagstein, F., Kjekshus, J., Vikstrand, J., El Alaf, D., Vitovec, J., Aldersheimer, J. et al. (2000) Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). MERIT-HF Study Group. JAMA 283, 1295–1302 CrossRef PubMed

22 CIBIS II Investigators and Committees (1999) The Cardiac Insufficiency Bisoprolol Study II (CIBIS II): a randomised trial. Lancet 353, 9–13 CrossRef PubMed

23 Packer, M., Bristow, M.R., Cohn, J.N., Colucci, W.S., Fowler, M.B., Gilbert, E.M. and Shuster, N.H. (1996) The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N. Engl. J. Med. 334, 1349–1355 CrossRef PubMed

24 Packer, M., Coats, A.J., Fowler, M.B., Katus, H.A., Krum, H., Mohacsi, P., Ruelau, J.L., Tendera, M., Castaigne, A., Roeccker, E.B. et al. (2001) Effect of carvedilol on survival in severe chronic heart failure. N. Engl. J. Med. 344, 1651–1658 CrossRef PubMed

25 Flather, M.D., Yusuf, S., Keber, L., Pfeffer, M., Hall, A., Murray, G., Torp-Pedersen, C., Ball, S., Pogue, J., Moye, L. et al. (2000) Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 355, 1575–1581 CrossRef PubMed

26 McMurray, J.J., Adamopoulos, S., Anker, S.D., Auricchio, A., Böhmann, F., Dickstein, K., Falk, V., Filippatos, G., Fonseca, C.A., Gomez-Sanchez, M.A. et al. (2012) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur. J. Heart Fail. 14, 803–869 CrossRef PubMed

27 Haldeman, G.A., Croft, J.B., Giles, W.H. and Rashidee, A. (1999) Hospitalisation of patients with heart failure: National Hospital Discharge Survey, 1985 to 1995. Am. Heart J. 137, 352–360 CrossRef PubMed

28 Jaagoo, P., Dawson, N. and Thomas, C. (1998) Outcomes of acute exacerbation of severe congestive heart failure. Arch. Intern. Med. 158, 1081–1089 CrossRef

29 Go, A.S., Mozaffarian, D., Roger, V.L., Benjamin, E.J., Berry, J.D., Borden, W.S., Dravata, D.M., Dai, S., Ford, E.S., Fox, C.S. et al. (2013) Heart disease and stroke statistics–2013 update: a report from the American Heart Association. Circulation 127, 64–245 CrossRef PubMed

30 Braunwald, E. (2013) Heart failure. JACC Heart Fail. 1, 1–20 CrossRef PubMed

31 Volpe, M., Rubattu, S. and Burnett, Jr, J. (2014) Natriuretic peptides in cardiovascular diseases: current use and perspectives. Eur. Heart J. 35, 419–425 CrossRef PubMed

32 McMurray, J.J., Pfeffer, M.A., Swedberg, K. and Dzau, V.J. (2004) Which inhibitor of the renin–angiotensin system should be used in chronic heart failure and acute myocardial infarction? Circulation 110, 3281–3288 CrossRef PubMed

33 Pitt, B., Chang, P and Timmermans, P.B. (1995) Angiotensin II receptor antagonists in heart failure: rationale and design of the evaluation of losartan in the elderly (ELITE) trial. Cardiovasc. Drugs Ther. 9, 693–700 CrossRef PubMed

34 Witherow, F.N., Helmy, A., Webb, D.J., Fox, K.A. and Newby, D.E. (2001) Bradykinin contributes to the vasodilator effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure. Circulation 104, 2177–2181 CrossRef PubMed

35 Witherow, F.N., Dawson, P., Ludlam, C.A., Fox, K.A. and Newby, D.E. (2002) Marked bradykinin-induced tissue plasminogen activator release in patients with heart failure maintained on long-term angiotensin-converting enzyme inhibitor therapy. J. Am. Coll. Cardiol. 40, 961–966 CrossRef PubMed

36 de Bold, A.J., Borenstein, H.B., Veress, A.T. and Sonnenberg, M. (1981) A rapid and potent natriuretic response to atrial natriuretic factor in chronic heart failure and acute myocardial infarction. N. Engl. J. Med. 344, 1651–1658 CrossRef PubMed

37 Misono, K.S., Grammer, R.T, Fukumi, H. and Inagami, T. (1984) Rat atrial natriuretic factor: isolation, structure and biological activities of four major peptides. Biochem. Biophys. Res. Commun. 123, 444–451 CrossRef PubMed

38 Flynn, T.G., de Bold, M.L. and de Bold, A.J. (1983) The amino acid sequence of an atrial peptide with potent diuretic and natriuretic properties. Biochem. Biophys. Res. Commun. 117, 859–865 CrossRef PubMed
Circulating N-terminal atrial natriuretic peptide as a marker for heart failure: evidence for an exquisite dual natriuretic hormonal and hemodynamic responses to peptide infusion. J. Hypertens. Suppl. 107, 223–241 CrossRef PubMed

54 Lerman, A., Gibbons, R.J., Rodeheffer, R.J., Bailey, K.R., McKinley, L.J., Heublein, D.M. and Burnett, Jr, J.C. (1993) Circulating N-terminal atrial natriuretic peptide as a marker for symptomless left-ventricular dysfunction. Lancet 341, 1105–1109 CrossRef PubMed

55 Seilhamer, J.J., Arfsten, A., Miller, J.A., Lundquist, P., Scarborough, R.M., Lewicki, J.A. and Porter, J.G. (1989) Human and canine gene homologs of porcine brain natriuretic peptide. Biochem. Biophys. Res. Commun. 165, 650–658 CrossRef PubMed

56 Yandle, T.G. and Richards, A.M. (2015) B-type natriuretic peptide circulating forms: analytical and bioactivity issues. Clin. Chim. Acta 448, 195–205 CrossRef PubMed

57 Grepin, C., Dagnino, L., Robitaille, L., Raberstroh, L., Antaky, T. and Nemer, M. (1994) A hormone-encoding gene identifies a pathway for cardiac but not skeletal muscle gene transcription. Mol. Cell. Biol. 14, 3115–3129 CrossRef PubMed

58 Hagihara, H., Sakaguchi, H., Itakura, M., Yoshimoto, T., Furuya, M., Tanaka, S. and Hirose, S. (1994) Autocrine regulation of rat chondrocyte proliferation by natriuretic peptide C and its receptor, natriuretic peptide receptor-B. J. Biol. Chem. 269, 10729–10733 PubMed

59 Hagihara, H., Sakaguchi, H., Lodhi, K.M., Suda, K. and Hirose, S. (1994) Subtype switching of natriuretic peptide receptors in rat chondrocytes during in vitro culture. J. Biolchem. 116, 1043–1049 PubMed

60 Suga, S., Nakao, K., Itoh, H., Komatsu, Y., Ogawa, Y., Hama, N. and Imura, H. (1992) Endothelial production of C-type natriuretic peptide and its marked augmentation by transforming growth factor-β1: Possible existence of ‘vascular natriuretic peptide system. J. Clin. Invest. 90, 1145–1149 CrossRef PubMed

61 Wu, C., Wu, F., Fan, J., Morser, J. and Wu, Q. (2003) Furin-mediated processing of Pro-C-type natriuretic peptide. J. Biol. Chem. 278, 25847–25852 CrossRef PubMed

62 Yeung, V.T., Ho, S.K., Nicholas, M.G. and Cockram, C.S. (1996) Binding of CNP-22 and CNP-53 to cultured mouse astrocytes and effects on cyclic GMP Peptides 17, 101–106 CrossRef PubMed

63 Totsume, K., Takahashi, K., Ohneda, M., Itoi, K., Murakami, O. and Mouri, T. (1994) C-type natriuretic peptide in the human central nervous system: distribution and molecular form. Peptides 15, 37–40 CrossRef PubMed

64 Stingo, A.J., Clavell, A.L., Heublein, D.M., Wei, C.M., Pittelkow, M.R. and Burnett, Jr, J.C. (1992) Presence of C-type natriuretic peptide in cultured human endothelial cells and plasma. Am. J. Physiol. 263, H1318–H1321 PubMed

65 Minamino, N., Makino, Y., Tateyama, H., Kangawa, K. and Matsuo, H. (1991) Characterization of immunoreactive human C-type natriuretic peptide in brain and heart. Biochem. Biophys. Res. Commun. 179, 535–542 CrossRef PubMed

66 Togashi, K., Kameya, T., Kurowsawa, T., Hasagawa, N. and Kawakami, M. (1992) Concentrations and molecular forms of C-type natriuretic peptide in brain and cerebrospinal fluid. Clin. Chem. 38, 2136–2139 PubMed

67 Wei, C.M., Heublein, D.M., Perrella, M.A., Lerman, A., Rodeheffer, R.J., McGregor, C.G., Edwards, W.D., Schaff, H.V. and Burnett, Jr, J.C. (1993) Natriuretic peptide system in human heart failure. Circulation 88, 1004–1009 CrossRef PubMed

68 Potter, L.R. (2005) Domain analysis of human transmembrane guanylyl cyclase receptors: implications for regulation. Front. Biosci. 10, 1205–1220 CrossRef PubMed

69 Chang, M.S., Lowe, D.G., Lewis, M., Hellmisch, R., Chen, E. and Goeddel, D.V. (1989) Differential activation by atrial and brain natriuretic peptides of two different receptor guanylyl cyclases. Nature 341, 68–72 CrossRef PubMed

70 Abbey, S.E. and Potter, L.R. (2002) Vasopressin-dependent inhibition of the C-type natriuretic peptide receptor, NPR-B/GC-B, requires elevated intracellular calcium concentrations. J. Biol. Chem. 277, 42423–42430 CrossRef PubMed
71 Porter, J.G., Arfsten, A., Fuller, F., Miller, J.A., Gregory, L.C. and Lewicki, J.A. (1990) Isolation and functional expression of the human atrial natriuretic peptide clearance receptor cDNA. Biochem. Biophys. Res. Commun. 171, 796–803 CrossRef PubMed

72 Wilcox, J.N., Augustine, A., Goeddel, D.V. and Lowe, D.G. (1991) Differential regional expression of three natriuretic peptide receptor genes within primate tissues. Mol. Cell. Biol. 11, 3454–3462 CrossRef PubMed

73 Ashman, D.F., Lipton, R., Melcic, M.M. and Price, T.D. (1963) Isolation of adenosine 3’, 5’-monophosphate and guanosine 3’, 5’-monophosphate from rat urine. Biochem. Biophys. Res. Commun. 11, 330–334 CrossRef PubMed

74 Lohmann, S.M., Vaandragter, A.B., Smolenski, A., Walter, U. and De Jonge, H.R. (1997) Distinct and specific functions of cGMP-dependent protein kinases. Trends. Biochem. Sci. 22, 307–312 CrossRef PubMed

75 Kaupp, U.B. and Seifert, R. (2002) Cyclic nucleotide-gated ion channels. Physiol. Rev. 82, 769–824 CrossRef PubMed

76 Sosa, R.E., Volpe, M., Marion, D.N., Atlas, S.A., Laragh, J.H., Vaughan, Jr, E.D. and Maack, T. (1986) Relationship between renal hemodynamic and natriuretic effects of atrial natriuretic factor. Am. J. Physiol. 250 3 Pt 2, F520–F524 PubMed

77 Kishimoto, I., Dubois, S.K. and Garbers, D.L. (1996) The heart communicates with the kidney exclusively through the guanylyl cyclase-A receptor: acute handling of sodium and water in response to volume expansion. Proc. Natl. Acad. Sci. U.S.A. 93, 6215–6219 CrossRef PubMed

78 Marin-Grez, M., Fleming, J.T. and Steinhausen, M. (1986) Atrial natriuretic peptide causes preglomerular vasoconstriction in rat kidney. Nature 324, 473–476 CrossRef PubMed

79 Harris, R.J., Thomas, D. and Morgan, T.O. (1987) Atrial natriuretic peptide inhibits angiotensin-stimulated proximal tubular sodium and water reabsorption. Nature 326, 697–698 CrossRef PubMed

80 Light, D.B., Corbin, J.D. and Stanton, B.A. (1990) Dual ion-channel regulation by cyclic GMP and cyclic GMP-dependent protein kinase. Nature 344, 336–339 CrossRef PubMed

81 Chabrier, R.E., Robert, E., Lorchampa, M.O., Plas, P. and Braquet, P. (1988) Regulation of atrial natriuretic factor receptors by angiotensin II in rat vascular smooth muscle cells. J. Biol. Chem. 263, 13199–202 PubMed

82 Gopi, V., Parthasarathy, A., Umadavi, S. and Vellaichamy, E. (2013) Angiotensin-II down-regulates cardiac natriuretic peptide receptor-A mediated anti-hypertrophic signaling in experimental rat hearts. Indian J. Exp. Biol. 51, 48–55 PubMed

83 Yoshimoto, T., Naruse, M., Naruse, K., Shionoya, K., Tanaka, M., Tanabe, A., Hagiwara, H., Hirose, S., Muraki, T. and Demura, H. (1996) Angiotensin II-dependent down-regulation of post-glomerular vasoconstriction in rat kidney. Nature 324, 1102–1107 CrossRef PubMed

84 Suga, S., Itoh, H., Komatsu, Y., Ogawa, Y., Hama, N., Yoshimasa, T. and Nakao, K. (1993) Cytokine-induced C-type natriuretic peptide (CNP) secretion from vascular endothelial cells–evidence for CNP as a novel autocrine/paracrine regulator from endothelial cells. Endocronology 133, 3038–3041 PubMed

85 Drewett, J.G., Fendly, B.M., Garbers, D.L. and Lowe, D.G. (1995) Natriuretic peptide receptor-B (guanylyl cyclase-B) mediates C-type natriuretic peptide relaxation of precontracted rat aorta. J. Biol. Chem. 270, 4668–4674 CrossRef PubMed

86 Furuya, M., Yoshida, M., Hayashi, Y., Ohnuma, N., Minamino, N., Kangawa, K. and Matsuo, H. (1991) C-type natriuretic peptide is a growth inhibitor of rat vascular smooth muscle cells. Biochem. Biophys. Res. Commun. 177, 927–931 CrossRef PubMed

87 Kohno, M., Yokokawa, K., Yasunari, K., Kano, H., Minami, M., Ueda, M. and Yoshikawa, J. (1997) Effect of natriuretic peptide family on the oxidized LDL-induced migration of human coronary artery smooth muscle cells. Circ. Res. 81, 585–590 CrossRef PubMed

88 Barton, M., Beny, J.L., d’Uscio, L.V., Wyss, T., Noll, G. and Lüscher, T.F. (1998) Endothelium-independent relaxation and hyperpolarization to C-type natriuretic peptide in porcine coronary arteries. J. Cardiovasc. Pharmacol. 31, 377–383 CrossRef PubMed

89 Burnett Jr, J.G., Granger, J.P. and Oppenorth, T.J. (1984) Effects of synthetic atrial natriuretic factor on renal function and renin release. Am. J. Physiol. 247, F863–F866 PubMed

90 Volpe, M., Odell, G., Kleinert, H.D., Müller, F., Camargo, M.J., Laragh, J.H., Maack, T., Vaughan, Jr, E.D. and Atlas, S.A. (1985) Effect of atrial natriuretic factor on blood pressure, renin, and aldosterone in Goldblatt hypertension. Hypertension 7 3 Pt 2, I43–I48 CrossRef PubMed

91 Lean, A., Racz, K., Guthkow, J., Nguyen, T.T., Cantin, M. and Genest, J. (1984) Specific receptor-mediated inhibition of synthetic atrial natriuretic factor of hormone-stimulated steroidogenesis in cultured bovine adrenal cells. Endocrinology 115, 1636–1638 CrossRef PubMed

92 Chartier, L., Schiffrin, E., Thibault, G. and Garcia, R. (1984) Atrial natriuretic factor inhibits the stimulation of aldosterone secretion by angiotensin II, ACTH and potassium in vitro and angiotensin II-induced steroidogenesis in vivo. Endocrinology 115, 2026–2028 CrossRef PubMed

93 Volpe, M., Cuocolo, A., Vecchione, F., Mele, A.F., Condorelli, M. and Trimarco, B. (1987) Vagal mediation of the effects of atrial natriuretic factor on blood pressure and arterial baroreflexes in the rabbit. Circ. Res. 60, 747–55 CrossRef PubMed

94 Volpe, M., Luca, N., Bigazzi, M.C., Vecchione, F., Lembo, G., Condorelli, M. and Trimarco, B. (1988) Atrial natriuretic factor potentiates forearm reflex vasconstriction induced by cardiopulmonary receptor deactivation in man. Circulation 77, 849–56 CrossRef PubMed

95 Volpe, M., Lembo, G., Condorelli, G., Luca, N., Lamenza, F., Indolfi, C. and Trimarco, B. (1990) Converting enzyme inhibition prevents the effects of atrial natriuretic factor on baroreflex responses in humans. Circulation 82, 1214–1221 CrossRef PubMed

96 Franco, F., Dubois, S.K., Peshock, R.M. and Shohet, R.V. (1998) Magnetic resonance imaging accurately estimates LV mass in a transgenic mouse model of cardiac hypertrophy. Am. J. Physiol. 274, H679–H683 PubMed

97 Barbee, R.W., Perry, B.D., Re, R.N., Mungo, J.P. and Field, L.J. (1994) Hemodynamics in transgenic mice with overexpression of atrial natriuretic factor. Circ. Res. 74, 747–751 CrossRef PubMed

98 Knowles, J.W., Esposito, G., Mao, L., Hageman, J.R., Fox, J.E., Smithies, O., Rockman, H.A. and Maeda, N. (2001) Pressure-independent enhancement of cardiac hypertrophy in natriuretic peptide receptor A-deficient mice. J. Clin. Invest. 107, 975–984 CrossRef PubMed

99 Kishimoto, I., Rossi, K. and Garbers, D.L. (2001) A genetic model provides evidence that the receptor for atrial natriuretic peptide (guanylyl cyclase-A) inhibits cardiac ventricular myocyte hypertrophy. Proc. Natl. Acad. Sci. U.S.A. 98, 2703–2706 CrossRef PubMed

100 Hayashi, D., Kudoh, S., Shiojima, I., Zou, Y., Harada, K., Shiomoyama, M., Imai, Y., Monzen, K., Yamazaki, T., Yasaki, Y. et al. (2004) Atrial natriuretic peptide inhibits cardiomyocyte hypertrophy through mitogen-activated protein kinase phosphatase-1. Biochem. Biophys. Res. Commun. 322, 310–319 CrossRef PubMed
101 Fujita, S., Shimojo, N., Terasaki, F., Otsuka, K., Hosotani, N., Kohda, Y., Tanaka, T., Nishioka, T., Yoshida, T., Hiroe, M. et al. (2013) Atrial natriuretic peptide exerts protective action against angiotensin II-induced cardiac remodeling by attenuating inflammation via endothelin-1/endothelin receptor A cascade. Heart Vessels 28, 646–657 CrossRef PubMed

102 Calderone, A., Thaik, C.M., Takahashi, N., Chang, D.L. and Colucci, W.S. (1998) Nitric oxide, atrial natriuretic peptide, and cyclic GMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblasts. J. Clin. Invest. 101, 812–818 CrossRef PubMed

103 Rubattu, S., Bigatti, G., Evangelista, A., Lanzani, C., Stanzione, R., Zagato, L., Manunta, R., Marchitti, S., Venturelli, V. and Bianchi, G. (2006) Association of atrial natriuretic peptide and type a natriuretic peptide receptor gene polymorphisms with left ventricular mass in human essential hypertension. J. Am. Coll. Cardiol. 48, 499–505 CrossRef PubMed

104 Hamad, A.M., Clayton, A., Islam, B. and Knox, A.J. (2003) Guanylyl cyclases, nitric oxide, natriuretic peptides, and airway smooth muscle function. Am. J. Physiol. Lung Cell. Mol. Physiol. 285, 1973–1983 CrossRef PubMed

105 Klinger, J.R., Petit, R.D., Curtin, L.A., Warburton, R.R., Wrenn, D.S., Steinhelper, M.E., Field, L.I. and Hill, N.S. (1993) Cardiopulmonary responses to chronic hypoxia in transgenic mice that overexpress ANP J. Appl. Physiol. 75, 198–205 PubMed

106 Klinger, J.R., Warburton, R.R., Pietras, L.A., Smithies, O., Swift, R. and Hill, N.S. (1999) Genetic disruption of atrial natriuretic peptide causes pulmonary hypertension in normoxic and hypoxic mice. Am. J. Physiol. 276, L968–L974 PubMed

107 Itoh, T., Nagaya, N., Murakami, S., Fujii, T., Iwase, T., Ishibashi-Ueda, H., Yutani, C., Yamagishi, M., Kimura, H. and Kangawa, K. (2004) C-type natriuretic peptide ameliorates monocrotaline-induced pulmonary hypertension in rats. Am. J. Respir. Crit. Care Med. 170, 1204–1211 CrossRef PubMed

108 Murakami, S., Nagaya, N., Itoh, T., Fujii, T., Iwase, T., Hamada, K., Kimura, H. and Kangawa, K. (2004) C-type natriuretic peptide attenuates bleomycin-induced pulmonary fibrosis in mice. Am. J. Physiol. Lung Cell. Mol. Physiol. 287, L1172–L1177 CrossRef PubMed

109 Sengenes, C., Berlan, M., Gisezinski, I., Lafontan, M. and Galitzky, J. (2000) Natriuretic peptides: a new lipolytic pathway in human adipocytes. FASEB J. 14, 1345–1351 CrossRef PubMed

110 Sengenes, C., Zia-Karoff-Girard, A., Moulin, A., Berlan, M., Bouloumii, A., Lafontan, M. and Galitzky, J. (2002) Natriuretic peptide-dependent lipolysis in fat cells is a prime specificity. Am. J. Physiol. Regul. Integr. Comp. Physiol. 283, R257–R265 CrossRef PubMed

111 Sengenes, C., Bouloumié, A., Hauner, H., Berlan, M., Busse, R., Lafontan, M. and Galitzky, J. (2003) Involvement of a cGMP-dependent pathway in the natriuretic peptide-mediated hormone-sensitive lipase phosphorylation in human adipocytes. J. Biol. Chem. 278, 48617–48626 CrossRef PubMed

112 Charles, C.J., Espiner, E.A., Nicholls, M.G., Richards, A.M., Yandle, T.G., Potter, A. and Kosoglou, T. (1996) Clearance receptors and endopeptidase 24.11: equal role in natriuretic peptide metabolism in conscious sheep. Am. J. Physiol. 271, R373–R380 PubMed

113 Ruskoaho, H. (1992) Atrial natriuretic peptide: synthesis, release, and metabolism. Pharmacol. Rev. 44, 479–602 PubMed

114 Nakao, K., Sugawara, A., Morii, N., Sakamoto, M., Yamada, T., Itoh, H., Shiono, S., Saito, Y., Nishimura, K., Ban, T. et al. (1986) The pharmacokinetics of alpha-human atrial natriuretic polypeptide in healthy subjects. Eur. J. Clin. Pharmacol. 31, 101–103 CrossRef PubMed

115 Yandle, T.G., Richards, A.M., Nicholls, M.G., Cuneo, R., Espiner, E.A. and Livesey, J.H. (1986) Metabolic clearance rate and plasma half life of alpha-human atrial natriuretic peptide in man. Life Sci 38, 1827–1833 CrossRef PubMed

116 Crozier, I.G., Nicholls, M.G., Ikrham, H., Espiner, E.A., Yandle, T.G. and Jans, S. (1986) Atrial natriuretic peptide in humans. Production and clearance by various tissues. Hypertension 8, I11–I15 CrossRef PubMed

117 Schutten, H.H., Henriksen, J.H. and Warberg, J. (1987) Organ extraction of atrial natriuretic peptide (ANP) in man. Significance of sampling site. Clin. Physiol. 7, 125–132 CrossRef PubMed

118 Hollister, A.S., Rodeheffer, R.J., White, F.J., Potts, J.R., Imada, T. and Inagami, T. (1989) Clearance of atrial natriuretic factor by lung, liver, and kidney in human subjects and the dog. J. Clin. Invest. 83, 623–628 CrossRef PubMed

119 Richards, A.M., Crozier I.G., Yandle, T.G., Espiner, E.A., Ikrham, H. and Nicholls, M.G. (1993) Brain natriuretic factor: regional plasma concentrations and correlations with haemodynamic state in cardiac disease. Br. Heart J. 69, 414–417 CrossRef PubMed

120 Maack, T., Suzuki, M., Almeida, F.A., Nussenzeig, D., Scarborough, R.M., McEnroe, G.A. and Lewicki, J.A. (1987) Physiological role of silent receptors of atrial natriuretic factor. Science 238, 675–678 CrossRef PubMed

121 Kerr, M.A. and Kenny, A.J. (1974) The purification and specificity of a neutral endopeptidase from rabbit kidney brush border. Biochem. J. 137, 477–488 CrossRef PubMed

122 Malfroy, B., Swerts, J.P., Guyon, A., Roques, B.P. and Schwartz, J.C. (1978) High-affinity enkephalin-degrading peptidase in brain is increased after morphine. Nature 276, 523–526 CrossRef PubMed

123 Sonnenberg, J.L., Sakane, Y., Jeng, A.Y., Koehn, J.A., Ansell, J.A., Wenngloe, L.P. and Ghai, R.D. (1988) Identification of protease 3.4.24.11 as the major atrial natriuretic factor degrading enzyme in the rat kidney. Peptides 9, 173–180 CrossRef PubMed

124 Stephenson, S.L. and Kenny, A.J. (1987) The hydrolysis of alpha-human atrial natriuretic peptide by pig kidney microvillar membranes is initiated by endopeptidase 24.11. Biochem. J. 243, 183–187 CrossRef PubMed

125 Vanneste, Y., Michel, A., Dimaline, R., Najdovski, T. and Deschot-Loeckman, M. (1988) Hydrolysis of alpha-human atrial natriuretic peptide in vitro by human kidney membranes and purified endopeptidase-24.11. Evidence for a novel cleavage site. Biochem. J. 254, 531–537 CrossRef PubMed

126 Watanabe, Y., Nakajima, K., Shimamori, Y. and Fujimoto, Y. (1997) Comparison of the hydrolysis of the three types of natriuretic peptides by human kidney neutral endopeptidase 24.11. Biochem. Mol. Med. 61, 47–51 CrossRef PubMed

127 Potter, L.R., Yoder, A.R., Flora, D.R., Antos, L.K. and Dickey, D.M. (2009) Natriuretic peptides: their structures, receptors, physiologic functions and therapeutic applications. Handb. Exp. Pharmacol. 191, 341–366 CrossRef PubMed

128 Kenny, A.J., Bourne, A. and Ingram, J. (1993) Hydrolysis of human and pig brain natriuretic peptides, urodilatin, C-type natriuretic peptide and some C-receptor ligands by endopeptidase-24.11. Biochem. J. 291, Pt 1, 83–88 CrossRef PubMed

129 Smith, M.W., Espiner, E.A., Yandle, T.G., Charles, C.J. and Richards, A.M. (2000) Delayed metabolism of human brain natriuretic peptide reflects resistance to neutral endopeptidase. J. Endocrinol. 167, 239–246 CrossRef PubMed

130 Dickey, D.M. and Potter, L.R. (2010) Human B-type natriuretic peptide is not degraded by meprin A. Biochem. Pharmacol. 80, 1007–1011 CrossRef PubMed

131 Duckworth, W.C., Bennett, R.G. and Hamel, F.G. (1998) Insulin degradation: progress and potential. Endocr. Rev. 19, 608–624 PubMed
132 Muller, D., Baumeister, H., Buck, F. and Richter, D. (1991) Atrial natriuretic peptide (ANP) is a high-affinity substrate for rat insulin-degrading enzyme. Eur. J. Biochem. 202, 285–292 CrossRef PubMed

133 Muller, D., Schulze, C., Baumeister, H., Buck, F. and Richter, D. (1992) Rat insulin-degrading enzyme: cleavage pattern of the natriuretic peptide hormones ANP BNP and CNP revealed by HPLC and mass spectrometry. Biochemistry 31, 11138–11143 CrossRef PubMed

134 Charles, C.J., Espiner, E.A., Nicholls, M.G., Richards, A.M., Yandle, T.G., Padrutt, A. and Kosoglu, T. (1996) Clearance receptors and endopeptidase 24.11: equal role in natriuretic peptide metabolism in conscious sheep. Am. J. Physiol. 271, R373–R380 PubMed

135 Koepke, J.P., Tyler, L.D., Trapani, A.J., Boyo, BR., Spear, K.L., Ollins, G.M. and Blaine, E.H. (1989) Interaction of non-guanyl-cyclase-linked atriopeptin receptor ligand and endopeptidase inhibitor in conscious rats. J. Pharmacol. Exp. Ther. 249, 172–176 PubMed

136 Kukkonen, P., Vuotteenaho, O. and Ruskoaho, H. (1992) Basal and volume expansion-stimulated plasma atrial natriuretic peptide concentrations and hemodynamics in conscious rats: effects of SCH 39,370, an endopeptidase inhibitor, and C-ANF-(4–23), a clearance receptor ligand. Endocrinology 130, 755–765 PubMed

137 Okolicany, J., McEnroe, GA., Koh, G.Y., Lewicki, J.A. and Maack, T. (1992) Clearance receptor and neutral endopeptidase-mediated metabolism of atrial natriuretic factor. Am. J. Physiol. 263, F546–F553 PubMed

138 Hashimoto, Y., Nakao, K., Hama, N., Imura, H., Mori, S., Yamaguchi, M., Yasuhara, M. and Hori, R. (1994) Clearance mechanisms of atrial and brain natriuretic peptides in rats. Pharm. Res. 11, 60–64 CrossRef PubMed

139 Shenker, Y., Sider, R.S., Ostafin, E.A. and Grekin, R.J. (1985) Plasma levels of immunoreactive atrial natriuretic factor in healthy subjects and in patients with edema. J. Clin. Invest. 76, 1684–1687 CrossRef PubMed

140 Volpe, M., Mele, A.F., Luca, N., Colino, P., Bondiolotti, G., Camargo, M.J., Atlas, S.A. and Tramarin, B. (1986) Carotid baroreceptor unloading decreases plasma atrial natriuretic factor in hypertensive patients. J. Hypertens. Suppl. 4, S519–S522 PubMed

141 Trimarco, B., Lembo, G., De Luca, N., Volpe, M., Ricciardelli, B., Condorelli, G., Rosiello, G. and Condorelli, M. (1989) Blunted sympathetic response to cardiopulmonary receptor unloading in hypertensive patients with left ventricular hypertrophy. A possible compensatory role of atrial natriuretic factor. Circulation 80, 883–892 CrossRef PubMed

142 Volpe, M., Tritto, C., DeLuca, N., Rubattu, S., Mele, A.F., Lembo, G., Enea, I., deCampana, P., Rendina, V. and Romano, M. (1992) Angiotensin converting enzyme inhibition restores cardiac and hormonal responses to volume overload in patients with dilated cardiomyopathy and mild heart failure. Circulation 86, 1800–1809 CrossRef PubMed

143 Raine, A.E., Erne, P., Burgisser, E., Müller, F.B., Bolli, P., Burkart, F. and Bühler, FR. (1986) Atrial natriuretic peptide and atrial pressure in patients with congestive heart failure. N. Engl. J. Med. 315, 533–537 CrossRef PubMed

144 Hensen, J., Abraham, W.T., Lesniewski, E.J., Levenson, B., Groves, B.M., Schröder, K., Schier, R.W. and Dürr, J. (1992) Atrial natriuretic peptide in patients with cardiac dysfunction. Kidney Int. 41, 1333–1339 CrossRef PubMed

145 Focaccio, A., Volpe, M., Ambrosio, G., Lembo, G., Pannain, S., Rubattu, S., Enea, I., Pignolosa, S. and Chiarriello, M. (1993) Angiotensin II directly stimulates release of atrial natriuretic factor in isolated rabbit hearts. Circulation 87, 192–198 CrossRef PubMed

146 Bae, E.H., Ma, S.K., Lee, J. and Kim, S.W. (2001) Altered regulation of renal nitric oxide and atrial natriuretic peptide systems in angiotensin II-induced hypertension. Regul. Pept. 170, 31–37 CrossRef PubMed

147 Hirsch, A.T., Creager, M.A. and Dzau, V.J. (1989) Relation of atrial natriuretic factor to vasoconstrictor hormones and regional blood flow in congestive heart failure. Am. J. Cardiol. 63, 211–216 CrossRef PubMed

148 Kanamori, T., Wada, A., Tsutamoto, T. and Kinoshita, M. (1995) Possible regulation of renin release by ANP in dogs with heart failure. Am. J. Physiol. 268, H2281–H2287 PubMed

149 Moe, G.W., Forster, C., de Bold, A.J. and Armstrong, F.W. (1990) Pharmacokinetics, hemodynamic, renal, and neurohormonal effects of atrial natriuretic factor in experimental heart failure. Clin. Invest. Med. 13, 111–118 PubMed

150 Cody, R.J., Atlas, S.A., Laragh, J.H., Kubo, S.H., Covit, A.B., Ryman, K.S., Shakhnovich, A., Pondolfino, K., Clark, M., Camargo, M.J. et al. (1986) Plasma levels and renal, hormonal, and hemodynamic responses to peptide infusion. J. Clin. Invest. 78, 1362–1374 CrossRef PubMed

151 Volpe, M., Mele, A.F., Indolfi, C., De Luca, N., De Luca, N., Lembo, G., Focaccio, A., Condorelli, M. and Trimarco, B. (1987) Hemodynamic and hormonal effects of atrial natriuretic factor in patients with essential hypertension. J. Am. Coll. Cardiol. 10, 787–93 CrossRef PubMed

152 Lohmeier, T.E., Mizelle, H.L., Reinhart, G.A., Montani, J.P., Hord, Jr, C.E. and Didlake, R.H. (1996) Atrial natriuretic peptide and sodium homeostasis in compensated heart failure. Am. J. Physiol. 271, R1353–R1363 PubMed

153 Costello-Boerrigter, L.C., Boerrigter, G. and Burnett, Jr, J.C. (2003) Revisiting salt and water retention: new diuretics, aquaretics, and natriuretics. Med. Clin. North. Am. 87, 475–491 CrossRef PubMed

154 Stevens, T.L., Burnett, Jr, J.C., Kinoshita, M., Matsuda, Y. and Redfield, M.M. (1995) A functional role for endogenous atrial natriuretic peptide in a canine model of early left ventricular dysfunction. J. Clin. Invest. 95, 1101–1108 CrossRef PubMed

155 Laragh, J.H. (1985) Atrial natriuretic hormone, the renin-aldosterone axis, and blood pressure-electrolyte homeostasis. N. Engl. J. Med. 313, 1330–1340 CrossRef PubMed

156 Harris, R.J., Thomas, D. and Morgan, T.O. (1987) Atrial natriuretic peptide inhibits angiotensin-stimulated proximal tubular sodium and water reabsorption. Nature 326, 697–698 CrossRef PubMed

157 Wada, A., Tsutamoto, T., Maeda, Y., Kanamori, T., Matsuda, Y. and Kinoshita, M. (1996) Endogenous atrial natriuretic peptide inhibits endothelin-1 secretion in dogs with severe congestive heart failure. Am. J. Physiol. 270, H1819–H1824 PubMed

158 Charloux, A., Piquard, F., Doutreleau, S., Brandenberger, G. and Gery, B. (2003) Mechanisms of renal hyperresponsiveness to ANP in heart failure. Eur. J. Clin. Invest. 33, 769–778 CrossRef PubMed

159 Mangiagfico, S., Costello-Boerrigter, L.C., Andersen, I.A., Cataliotti, A. and Burnett, Jr, J.C. (2013) Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics. Eur. Heart J. 34, 886–893 CrossRef PubMed

160 Fielitz, J., Dandorf, A., Pragia, R., Ehler, E., Zurbrügg, H.R., Bartunek, J., Hetzer, R. and Regitz-Zagrosek, V. (2002) Neutral endopeptidase is activated in cardiomyocytes in human aortic valve stenosis and heart failure. Circulation 105, 286–289 CrossRef PubMed

161 McKie, P.M., Ichiki, T. and Burnett, Jr, J.C. (2012) M-atrial natriuretic peptide: a novel antihypertensive protein therapy. Curr. Hypertens. Rep. 14, 62–69 CrossRef PubMed
162 McKie, P.M., Cataliotti, A., Ichiki, T., Sangaralingham, S.J., Chen, H.H. and Burnett, Jr, J.C. (2013) Natriuretic peptide and NT-proBNP in a canine model of experimental acute hypertensive heart failure: a differential actions of 2 cGMP activating therapeutics. J. Am. Heart Ass. 3, e000206. doi: 10.1161/JAHA.113.000206

163 Colucci, W.S., Eltayeb, U., Horton, D.P., Abraham, W.T., Bourge, R.C., Johnson, A.D., Wagoner, L.E., Givertz, M.M., Liang, C.S., Neibaur, M. et al. (2006) Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. NesiRitude Study Group. N. Engl. J. Med. 343, 246–253 CrossRef PubMed

164 Sackner-Bernstein, J.D., Kowalski, M., Fox, M. and Aaronson, K. (2005) Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA 293, 1900–1905 CrossRef PubMed

165 O’Connor, C.M., Starling, R.C., Hernandez, A.F., Armstrong, P.W., Dickstein, K., Hasselblad, V., Heizer, G.M., Komajda, M., Massie, B.M., McMurray, J.J. et al. (2011) Effect of nesiritide in patients with acute decompensated heart failure. N. Engl. J. Med. 365, 32–43 CrossRef PubMed

166 vonLueder, T.G., Sangaralingham, S.J., Wang, B.H., Kompa, A.R., Atar, D., Burnett, Jr, J.C. and Krum, H. (2013) Renin-angiotensin blockade combined with natriuretic peptide system augmentation: novel therapeutic concepts to combat heart failure. Circ. Heart Fail. 6, 594–605 CrossRef PubMed

167 Schweitz, H., Vigne, P., Moinier, D., Frelin, C. and Lazdunski, M. (1992) A new member of the natriuretic peptide family is present in the venom of the green mamba (Dendroaspis angusticeps). J. Biol. Chem. 267, 13928–13932 PubMed

168 Dickey, D.M. and Potter, L.R. (2011) Dendroaspis natriuretic peptide and the designer natriuretic peptide, CD-NP are resistant to proteolytic inactivation. J. Mol. Cell. Cardiol. 51, 67–71 CrossRef PubMed

169 Martin, F.L., Sangaralingham, S.J., Huntley, B.K., McKie, P.M., Ichiki, T., Chen, H.H., Konjek, J., Harders, G.E. and Burnett, Jr, J.C. (2012) CD-NP: a novel engineered dual guanylylcyclase activator with anti-fibrotic actions in the heart. PLoS One 7, e52422 CrossRef PubMed

170 Neutel, J., Rolston, W., Maddox, S., Goldsmith, S., Koren, M., Bill, V.A., Burnett, J. and Lieu, H.D. (2012) Initial experience with subcutaneous infusion of cenderitide in chronic heart failure patients. J. Am. Coll. Cardiol. 59, E1037 CrossRef PubMed

171 Hirsch, J.R., Meyer, M. and Forssmann, W.G. (2001) ANP and bradykinin peptides in vitro: who is who in the kidney. Eur. J. Med. Res. 6, 594–605 CrossRef PubMed

172 Lee, C. and Burnett, Jr, J.C. (2007) Discovery of a novel synthetic natriuretic peptide, CU-PN. J. Card. Fail. 13 6 Suppl. 2, S74 CrossRef PubMed

173 Erdoes, E.G. and Skidgel, R.A. (1989) Neutral endopeptidase 24.11 (enkephalasein) and related regulators of peptide hormones. FASEB J. 3, 145–151 PubMed

174 Roques, B.P., Noble, F., Daugdé, V., Fournié-Zaluski, M.C. and Beaumont, A. (1995) Neutral endopeptidase 24.11: structure, inhibition, and experimental and clinical pharmacology. Pharmacol. Rev. 45, 87–146 PubMed

175 Yamamoto, K., Chappell, M.C., Brosnihan, K.B. and Ferrario, C.M. (1992) In vivo metabolism of angiotensin I by neutral endopeptidase (EC 3.4.24.11) in spontaneously hypertensive rats. Hypertension 19, 692–696 CrossRef PubMed

176 Richards, A.M., Wittert, G.A., Espiner, E.A., Yandle, T.G., Ikram, H. and Frampton, C. (1992) Effect of inhibition of endopeptidase 24.11 on responses to angiotensin II in human volunteers. Circ. Res. 71, 1501–1507 CrossRef PubMed

177 Ivata, N., Tsukui, S., Takaki, Y., Shirotani, K., Lu, B., Gerard, N.P., Gerard, C., Hama, E., Lee, H.J. and Saido, T.C. (2001) Metabolic regulation of brain Aβ by neprilysin. Science 292, 1550–1552 CrossRef PubMed

178 Jeng, A.Y., Savage, P., Bell, M.E., Bruseo, C.W., Hoye, D., Fink, C.A. and Trapani, A.J. (2002) CGS 34226, a thiol-based dual inhibitor of endothelin converting enzyme-1 and neutral endopeptidase 24.11. Clin. Sci. 103 suppl 1, 98S–101S CrossRef PubMed

179 Campbell, D.J. (2003) Vasopeptidase inhibition. A double-edge sword? Hypertension 41, 383–389 CrossRef PubMed

180 Richards, A.M., Wittert, G.A., Crozier, I.G., Espiner, E.A., Yandle, T.G., Ikram, H. and Frampton, C. (1993) Chronic inhibition of endopeptidase 24.11 in essential hypertension: evidence for enhanced atrial natriuretic peptide and angiotensin II. J. Hypertens. 11, 407–416 CrossRef PubMed

181 Campbell, D.J., Anastasopoulos, F., Duncan, A.M., James, G.M., Kladis, A. and Briscoe, T.A. (1998) Effects of neutral endopeptidase inhibition and combined angiotensin converting enzyme and neutral endopeptidase inhibition on angiotensin and bradykinin peptides in rats. J. Pharmacol. Exp. Ther. 287, 567–577 PubMed

182 Ura, N., Carretero, O.A. and Erdos, E.G. (1987) Role of renal endopeptidase 24.11 in kinin metabolism in vitro and in vivo. Kidney Int. 32, 507–513 CrossRef PubMed

183 Smits, G.J., McGraw, D.E. and Trapani, A.J. (1999) Interaction of ANP and bradykinin during endopeptidase 24.11 inhibition: renal effects. Am. J. Physiol. 288, F1417–F1424 PubMed

184 Schriever, J.A., Broudy, E.F. and Hassen, A.H. (1996) Endopeptidase inhibitors decrease myocardial ischemia/reperfusion injury in an in vivo rabbit model. J. Pharmacol. Exp. Ther. 276, 1034–1040 PubMed

185 Yang, K.P., Liu, Y.H., Peterson, E. and Carretero, O.A. (1997) Effect of neutral endopeptidase 24.11 inhibition on myocardial ischemia/reperfusion injury: the role of kinins. J. Cardiovasc. Pharmacol. 29, 250–256 CrossRef PubMed

186 Piedimonte, G., Nadel, J.A., Long, C.S. and Hoffman, J.I.E. (1994) Neutral endopeptidase in the heart: Neutral endopeptidase inhibition prevents isoproterenol-induced myocardial hypoperfusion in rats by reducing bradykinin degradation. Circ. Res. 75, 770–779 CrossRef PubMed

187 Galli, A. and Lombardi, F. (2014) Nesiritide inhibition for heart failure. N. Engl. J. Med. 371, 2335 CrossRef PubMed

188 Northridge, D.B., Jardine, A.G., Ababaster, C.T.,巴拉克, R.L., Connell, J.M., Dargie, H.J., Dilly, S.G., Findlay, I.N., Lever, A.F. and Smans, G.M. (1989) Effects of UK 69 578: a novo atriotpeptidase inhibitor. Lancet 2, 591–593 CrossRef PubMed

189 Richards, M., Espiner, E., Frampton, C., Ikram, H., Yandle, T., Sopwith, M. and Cuvelier, N. (1990) Inhibition of endopeptidase EC 24.11 in humans: renal and endocrine effects. Hypertension 16, 269–276 CrossRef PubMed

190 Favrat, B., Burnier, M., Nussberger, J., Lecomte, J.M., Brouard, R., Waember, B. and Brunner, H.R. (1995) Neutral endopeptidase versus angiotensin converting enzyme inhibition in essential hypertension. J. Hypertens. 13, 797–804 CrossRef PubMed

191 Ando, S., Rahman, M.A., Butler, G.C., Senn, B.L. and Floras, J.S. (1995) Comparison of candesartan and atenolol natriuretic factor in healthy men: effects on hemodynamics, sympathetic activity, heart rate variability, and endothelin. Hypertension 26, 1160–1166 CrossRef PubMed

192 Bevan, E.G., Connell, J.M., Doyle, J., Carmichael, H.A., Davies, D.L., Lorimer, A.R. and McInnes, G.T. (1992) Candesartan, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertension. J. Hypertens. 10, 607–613 CrossRef PubMed

193 Kentsch, M., Otter, W., Drummer, C., Nägge, A., Gezer, R. and Müller-Esch, G. (1996) Neutral endopeptidase 24.11 inhibition may not exhibit beneficial haemodynamic effects in patients with congestive heart failure. Eur. J. Clin. Pharmacol. 51, 269–272 CrossRef PubMed

194 Nussberger, J., Cugno, M., Amstutz, C., Cicardi, M., Pellacani, A. and Agostini, A. (1998) Plasma bradykinin in angio-oedema. Lancet 351, 1693–1697 CrossRef PubMed
209 Solomon, S.D., Zile, M., Pieske, B., Voors, A., Shah, A., Kraigher-Kramer, E., Shi, V., Bransford, T., Takeuchi, M., Gong, J. et al. (2012) The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet 380, 1387–1395 CrossRef PubMed

210 McMurray, J.J., Packer, M., Desai, A.S., Gong, J., Lefkowitz, M.P., Rizkala, A.R., Rouleau, J.L., Shi, V.C., Solomon, S.D., Swedberg, K. et al. (2014) Angiotensin-neprilysin inhibition versus enalapril in heart failure. N. Engl. J. Med. 371, 993–1004 CrossRef PubMed

211 Green, C.P., Porter, C.B., Bresnahan, D.R. and Spertus, J.A. (2000) Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure. J. Am. Coll. Cardiol. 35, 1245–1255 CrossRef PubMed

212 Packe, M., McMurray, J.J., Desai, A.S., Gong, J., Lefkowitz, M.P., Rizkala, A.R., Rouleau, J.L., Shi, V.C., Solomon, S.D., Swedberg, K. et al. (2015) Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation 131, 54–61 CrossRef PubMed

Reference deleted PubMed

213 Jessup, M. (2014) Neprilysin inhibition – a novel therapy for heart failure. N. Engl. J. Med. 371, 1062–1064 CrossRef PubMed

214 Pitt, B., Segal, R., Martinez, F.A., Meurers, G., Cowley, A.J., Thomas, I., Deedwania, P.C., Ney, D.E., Snavely, D.B. and Chang, R. (1997) Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 349, 747–52 CrossRef PubMed

215 Pfeffer, M.A., McMurray, J.J., Velazquez, E.J., Rouleau, J.L., Kober, L., Maggioni, A.P., Solomon, S.D., Swedberg, K., de Werf, F., White, H. et al. (2003) Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N. Engl. J. Med. 349, 1893–1906 CrossRef PubMed

216 Cohn, J.N. and Tognoni, G. (2001) A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N. Engl. J. Med. 345, 1667–1675 CrossRef PubMed

217 Young, J.B., Dunlap, M.E., Pfeffer, M.A., Probstfield, J.L., Cohen-Solal, A., Dietz, R., Granger, C.B., Hradec, J., Kuch, J., Mckelvie, R.S. et al. (2004) Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-risk ventricular ejection fraction trial. Circulation 110, 2618–2629 CrossRef PubMed

218 Klaiber, M., Kruse, M., Völker, K., Feil, R., Freichel, M., Gerling, A., Feil, S., Dietrich, A., Londoño, E.J., Baba, H.A. et al. (2010) Novel insights into the mechanisms mediating the local antihypertrophic effects of cardiac atrial natriuretic peptide: role of cGMP-dependent protein kinase and RGS2. Basic Res. Cardiol. 105, 583–595 CrossRef PubMed

219 Langenickel, T.H. and Dole, W.P. (2012) Angiotensin receptor-neprilysin inhibition with LCZ696: a novel approach for the treatment of heart failure. Drug Discov. Today Ther. Strateg. 9, e131–e139 CrossRef

220 Kim, D., Alzawa, T., Wei, H., Pi, X., Rybalkin, S.D., Berk, B.C. and Yan, C. (2005) Angiotensin II increases phosphodiesterase SA expression in vascular smooth muscle cells: a mechanism whereby which angiotensin II antagonizes cGMP signaling. J. Mol. Cell. Cardiol. 38, 175–84 CrossRef PubMed

221 Frantz, S., Klaiber, M., Baba, H.A., Oberwinkler, H., Völker, K., Gajner, B., Bayer, B., Aheier, M., Schuh, K., Feil, R. et al. (2013) Stress-dependent dilated cardiomyopathy in mice with cardiomyocyte-restricted inactivation of cyclic GMP-dependent protein kinase I. Eur. Heart. J. 34, 1233–1244 CrossRef PubMed
Granger, C.B., McMurray, J.J., Yusuf, S., Held, P., Michelson, E.L., Olofsson, B., Ostergren, J., Pfeffer, M.A. and Swedberg, K. (2003) Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-alternative trial. Lancet 362, 772–776

Williams, B., Cockcroft, J.R., Kario, K., Zappe, D.H., Cardenas, P., Hester, A., Brunel, P. and Zhang, J. (2014) Rationale and study design of the Prospective comparison of Angiotensin Receptor nepriylisin inhibitor with Angiotensin receptor blocker MEasuring arterial stiffness in the eldERly (PARAMETER) study. BMJ Open 4, e004254

Received 6 July 2015/14 September 2015; accepted 28 September 2015
Version of Record published 4 December 2015, doi: 10.1042/CS20150469